CSF1r inhibitor compositions and methods for treating prader-willi syndrome
CSF1R inhibitors like PLX5622 provide a novel therapeutic approach for Prader-Willi syndrome by depleting microglia and modulating immune response, effectively improving metabolic function and reducing symptoms.
Patent Information
- Application Number
- PCT/US2026/028127
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Prader-Willi syndrome (PWS) has no cure and current treatments focus on growth hormone therapy and food intake supervision, leading to a high caregiver burden, with an urgent need for new therapeutic strategies.
Administering a colony stimulating factor 1 receptor (CSF1R) inhibitor, such as PLX5622, to deplete microglia and modulate the immune response, improving metabolic function in PWS patients.
CSF1R inhibitors like PLX5622 lead to significant weight loss, reduced food intake, improved glucose tolerance, and downregulated inflammatory and lipogenic gene expression in the liver, addressing metabolic abnormalities in PWS.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000022_0001 
Figure 00000064_0000
Abstract
Description
[0001] Docket No. 103362-109W01
[0002] CSF1R INHIBITOR COMPOSITIONS AND METHODS
[0003] FOR TREATING PRADER-WILLI SYNDROME
[0004] CROSS REFERENCE TO RELATED APPLICATIONS
[0005] This application claims the benefit of and priority to U.S. Provisional Patent Application 63 / 806,838, filed May 16, 2025, which is incorporated by reference herein in its entirety.
[0006] FIELD OF THE INVENTION
[0007] The present disclosure relates to methods for treating Prader-Willi syndrome (PWS) comprising administering to a subject in need thereof a colony stimulating factor 1 receptor (CSF1R) inhibitor, including but not limited to the CSF1R inhibitor PLX5622, or a pharmaceutically acceptable salt thereof.
[0008] INCORPORATION BY REFERENCE
[0009] The contents of the xml file named “103362-109WO1-ST26” which was created on April 20, 2026, and is 140,834 bytes in size, are hereby incorporated by reference in their entirety.
[0010] BACKGROUND OF THE INVENTION
[0011] Prader-Willi syndrome (PWS) is a rare genetic disease, occurring in approximately 1 in 15,000 individuals, and is caused by the loss of function of paternally inherited copy of chromosome 15qll-ql32,3. PWS patients display developmental delays, intellectual and cognitive impairment, behavioral and neuropsychiatric abnormalities, endocrine dysfunction, hypothalamic hypogonadism, and constant sense of hunger (hyperphagia) that often leads to obesity and many obesity-related complications.
[0012] PWS has no cure, and the standard of care is limited to growth hormone therapy and strict supervision of food intake. The high level of caregiver burden for PWS is estimated to exceed that of caregivers for patients with Alzheimer’s and traumatic brain injury.
[0013] There is an urgent unmet need for new therapeutic strategies in the treatment of PWS.Docket No. 103362-109W01
[0014] SUMMARY OF THE INVENTION
[0015] It has been surprisingly and unexpectedly discovered herein that the use of a colony stimulating factor 1 receptor (CSF1R) inhibitor, for example including but not limited to PLX5622, leads to improved metabolic function in Prader-Willi syndrome (PWS).
[0016] Based on the clinical and preclinical data implicating a role of microglia in the pathogenesis of PWS, preclinical testing was conducted using a small molecule CSF1R inhibitor drug PLX5622 to mediate microglia depletion in PWS murine model Magel2-null mice. Surprisingly, chronic PLX5622 treatment improved metabolic function in middle-aged female Magel2-null mice, resulting in significant reduction in food intake (see, e.g., FIG. 1 IF of Example 2) and improved glucose tolerance (see, e.g., FIG. 12B of Example 2), which unexpectedly was associated with robust downregulation of macrophage markers and genes involved in immune response in the liver (see, e.g., FIG. 17) together with suppression of genes critical for hepatic glucose production and de novo lipogenesis (see, e.g., FIG. 18 of Example 2).
[0017] In some embodiments, provided herein are novel methods for the treatment of PWS using an immune-modulatory CSF1R inhibitor. This class of small molecule CSF1R inhibitor drugs can be administered orally and have been previously investigated in clinical trials for cancer treatment, and therefore possess drug repurposing potential for PWS.
[0018] As described herein, microglia were partially depleted with CSF1R inhibitor PLX5622 in middle-aged (9-10-months) Magel2-null mice (see, e.g., FIG. 15, 16B of Example 2). PLX5622 treatment resulted in considerable body weight loss in Magel-2 null and WT mice (see, e.g., FIG. 11C of Example 2), as well as significant decreased food intake (see, e.g., FIG.
[0019] 1 IF of Example 2), and significant improvement in glucose metabolism selectively in Magel2-null mice (see, e.g., FIG. 12B of Example 2). These metabolic improvements were associated with anti-inflammatory gene signature in the liver and reduced hepatic signaling pathways involved in gluconeogenesis and de novo lipogenesis specifically in Magel2-null mice. These results suggest that a CSF1 inhibitor, for example including but not limited to PLX5622, is effective in the treatment of PWS-related metabolic abnormalities.
[0020] Indeed, it was surprisingly discovered herein the profound liver effects of PLX5622 in the PWS model Magel2-null mice. The data herein show a PLX5622-induced hepatic gene expression signature characterized as robust collective downregulation of macrophage markers and inflammatory genes (see, e.g., FIG. 17 of Example 2), indicating depletion of liver macrophages in the Magel2-null mice which was independent of age (see, e.g., FIG. 5A-5B, 6A-6B). Unexpectedly, PLX5622 reduced the mRNA and protein levels of PKCe and alsoDocket No. 103362-109W01
[0021] decreased levels of SREBP1, FASN, and G6PC (see, e.g., FIG. 6). These findings are contrary to the literature that shows chronic PLX5622 treatment in wild type mice depleted macrophages in multiple organs including adipose tissue, lung, and colon but not in the liver. In addition, a biphasic pattern during the glucose tolerance has been described in normal mice, with initial improvement followed by impairment of whole-body glucose tolerance after long-term PLX5622 treatment (Bosch et al. Diabetologia 2023, 66:2292-2306). Interestingly, it was also found that CSF1R inhibitor treatment led to opposing regulation of liver enzyme and signaling molecule genes depending on genotype, including Fasn, Scdl, Gpat, Scd2, G6pc, and Prkce (see FIG. 18 of Example 2).
[0022] This improvement provides a significant advance in the state of the art of treatment of PWS and other inflammatory diseases.
[0023] Specific benefits of a CSF1R inhibitor, including but not limited to PLX5622, as described herein include one or more of:
[0024] (i) considerable weight loss (see, e.g., FIG. IB of Example 1; FIG. 11C of Example 2); (ii) increased lean mass and decreased fat mass (see, e.g., FIG. IF, ID of Example 1); (iii) significantly decreased food intake (see, e.g., FIG. 1G of Example 1; FIG. 11F of Example 2);
[0025] (iv) improved glucose tolerance (see, e.g., FIG. 1H of Example 1 ; FIG. 12 B of Example 2);
[0026] (v) altered hypothalamic gene expression (see, e.g., FIG. 3A-3B) and adipose tissue gene expression (see, e.g., FIG. 4A-4D); and
[0027] (vi) downregulated inflammatory and lipogenic gene expression in the liver (see, e.g., FIG 5A-5B, 6A-6B).
[0028] While not wishing to be bound by any one theory, CSF1R inhibition by PLX5622 leads to metabolic improvement in PWS model Magel2-null mice in an age-dependent manner. PLX5622 treatment results in depletion of microglia, downregulation of macrophage markers and genes involved in immune response in the liver, and suppression of genes critical for hepatic glucose production (HGP) and lipogenesis in the middle-aged mice. In addition, CSF1R inhibition by PLX5622 reduces food intake independent of age while hyperphagia is a key feature of PWS. These data provide evidence in support of developing immune-modulatory therapeutics for the treatment of PWS, a genetic disease in urgent need of new therapeutic strategies.Docket No. 103362-109W01
[0029] In one aspect provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating Prader-Willi Syndrome (PWS) in a subject in need thereof, comprising administering to the subject an inhibitor of colony stimulating factor 1 receptor (CSF1R).
[0030] In one aspect, provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of structure:
[0031]
[0032] F (PLX5622), or a pharmaceutically acceptable salt thereof.
[0033] In one aspect, provided herein is a method for reducing body weight in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0034] In one aspect, provided herein is a method for decreasing fat mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0035] In one aspect, provided herein is a method for increasing lean mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0036] In one aspect, provided herein is a method for decreasing food intake in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0037] In one aspect, provided herein is a method for improving glucose tolerance in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0038] In one aspect, provided herein is a method for decreasing free fatty acid levels in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0039] In one aspect, provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising: (i) obtaining a sample from the subject; (ii) measuring the expression level of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC, or a combination thereof, in the sample compared to a control; and (iii) if the levels of one or more of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC are elevated compared to control, then administering to the subject a CSF1R inhibitor.
[0040] In some embodiments, the subject is an adult. In some embodiments, the subject is a child. In some embodiments, the subject is a human.Docket No. 103362-109W01
[0041] A summary of embodiments of the invention is described in further detail below.
[0042] BRIEF DESCRIPTION OF THE FIGURES
[0043] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate certain examples of the present disclosure and together with the description, serve to explain, without limitation, the principles of the disclosure. Like numbers represent the same elements throughout the figures.
[0044] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0045] FIG. 1A-1H show in vivo metabolic effects of PLX5622 in middle-aged Magel2-null mice. Data are means ± SEM. n=5 per group. * P<0.05, ** P<0.01.
[0046] FIG. 1 A shows a graph of body weight of mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Body weight as measured in grams (g) is represented on the y-axis, while duration of treatment is represented on the x-axis in weeks.
[0047] FIG. IB shows Body weight change (Percentage of baseline). Body weight change from baseline (% Baseline) is represented on the y-axis, while duration of treatment is represented on the x-axis in weeks.
[0048] FIG. 1C shows Adiposity (i.e., fat mass) at weeks 0 and 4 on PLX5622 compared to control. Fat mass as a percentage of body weight (% BW) is represented on the y-axis, while weeks on PLX5622 (or control) is represented on the x-axis.
[0049] FIG. ID shows Adiposity change as a percentage of baseline for PLX5622 treatment compared to control. Fat mass change as a percent of baseline (% Baseline) is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0050] FIG. IE shows Relative lean mass at weeks 0 and 4 on PLX5622 compared to control. Lean mass as a percentage of body weight (% BW) is represented on the y-axis, while weeks on PLX5622 (or control) is represented on the x-axis.
[0051] FIG. IF shows Relative lean mass change as a percentage of baseline for PLX5622 treatment compared to control. Lean mass change as a percent of baseline (% Baseline) is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.Docket No. 103362-109W01
[0052] FIG. 1G shows Average daily food intake. Average food intake from week 1 to week 6 post PLX treatment as measured in grams per day (g / day) is represented on the y-axis, while treatment condition is represented on the x-axis.
[0053] FIG. 1H shows Glucose tolerance test after 6 weeks PLX treatment. Blood glucose concentration (mg / dL) is represented on the y-axis, while time in minutes (min) after glucose injection is represented on the x-axis.
[0054] FIG. 2A-2H show Tissue weight and serum biomarkers in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. * P<0.05.
[0055] FIG. 2A shows Tissue weight for mice administered PLX5622 compared to control. Tissue weight as measured in grams (g) is represented on the y-axis for different tissues represented on the x-axis. BAT, brown adipose tissue; iWAT, inguinal white adipose tissue; gWAT, gonadal white adipose tissue; rWAT, retroperitoneal white adipose tissue.
[0056] FIG. 2B shows Relative tissue weight (percentage of body weight) for mice administered PLX5622 compared to control. Relative tissue weight, measured as percent of baseline (% BW), is represented on the y-axis for different tissues represented on the x-axis. BAT, brown adipose tissue; iWAT, inguinal white adipose tissue; gWAT, gonadal white adipose tissue; rWAT, retroperitoneal white adipose tissue.
[0057] FIG. 2C shows Serum leptin for mice administered PLX5622 compared to control. Serum leptin as measured in ng / mL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0058] FIG. 2D shows Serum insulin for mice administered PLX5622 compared to control. Serum insulin as measured in ng / mL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0059] FIG. 2E shows Serum glucose for mice administered PLX5622 compared to control. Serum glucose as measured in mg / dL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0060] FIG. 2F shows insulin resistance for mice administered PLX5622 compared to control. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0061] FIG. 2G shows Serum triglyceride for mice administered PLX5622 compared to control. Serum triglyceride as measured in mg / dL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.Docket No. 103362-109W01
[0062] FIG. 2H shows Serum free faty acids for mice administered PLX5622 compared to control. Serum free fatty acids as measured in pM is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0063] FIG. 3A-3D show Hypothalamic alterations in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. * P<0.05, ** P<0.01, *** PO.OOl.
[0064] FIG. 3A shows Relative expression of microglia-related genes. Relative mRNA levels are shown on the y-axis for different microglia-related genes represented on the x-axis.
[0065] FIG. 3B shows Relative expression of genes involved in energy balance regulation. Relative mRNA levels are shown on the y-axis for different energy balance regulation genes represented on the x-axis.
[0066] FIG. 3C shows Western bloting of Ibal and Vinculin for mice administered PLX5622 (PLX (+)) compared to control (PLX (-)). Vinculin is included as a loading control.
[0067] FIG. 3D shows Quantification of Western bloting in FIG. 3C. The ratio of Ibal to Vinculin band intensity is represented on the y-axis by arbitrary units for the treatment groups PLX5622 (PLX (+)) or control (PLX (-)) represented on the x-axis.
[0068] FIG. 4A-4D show Adipose tissue gene expression in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. * P<0.05, ** P<0.01.
[0069] FIG. 4A-4B show Relative gene expression in the inguinal white adipose tissue (iWAT). Relative mRNA levels are shown on the y-axis for different genes represented on the x-axis.
[0070] FIG. 4C-4D show Relative gene expression in the brown adipose tissue (BAT). Relative mRNA levels are shown on the y-axis for different genes represented on the x-axis.
[0071] FIG. 5A-5B show liver gene expression in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. * P<0.05, ** P<0.01, *** P<0.001.
[0072] FIG. 5A shows relative expression of immune or inflammatory genes. Relative mRNA levels are shown on the y-axis for different immune or inflammatory genes represented on the x-axis.
[0073] FIG. 5B shows relative expression of genes involved in lipogenesis and gluconeogenesis. Relative mRNA levels are shown on the y-axis for different genes involved in lipogenesis and gluconeogenesis represented on the x-axis.
[0074] FIG. 6A-6C show Liver Western bloting in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. * P<0.05.Docket No. 103362-109W01
[0075] FIG. 6A shows Western blotting for FASN, ChREBP, SREBP1, PKCepsilon, pS473 AKT, and t-AKT for mice administered PLX5622 (PLX (+)) compared to control (PLX (-)). Beta-actin is included as a loading control.
[0076] FIG. 6B shows Quantification of the Western blots of FIG. 6A. The ratio of FASN, ChREBP, SREBP1, PKCepsilon, pS473 AKT, or t-AKT to corresponding Beta- Actin band intensity is represented on the y-axis by arbitrary units for the treatment groups PLX5622 (PLX (+)) or control (PLX (-)) represented on the x-axis.
[0077] FIG. 6C shows Liver triglyceride level.
[0078] FIG. 7A-7H show in vivo metabolic effects of PLX5622 in young Magel2-null mice. Data are means ± SEM. Sample size: n=4 WT / PLX (-), n=3 Magel2-null / PLX (-), n=4 Magel2-null / PLX(+). ** P<0.01, *** PO.OOl.
[0079] FIG. 7 A shows a graph of body weight of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Body weight as measured in grams (g) is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0080] FIG. 7B shows Body weight change (Percentage of baseline) of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Body weight change as measured in % of baseline is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0081] FIG. 7C shows Adiposity of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Fat mass as measured in percent of body weight is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0082] FIG. 7D shows Adiposity change (Percentage of baseline) of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Fat mass change as measured in percent of baseline is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0083] FIG. 7E shows Relative lean mass of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Lean mass as measured in percent of body weight is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.Docket No. 103362-109W01
[0084] FIG. 7F shows Relative lean mass change (Percentage of baseline) of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Lean mass change as measured in percent of baseline is represented on the y-axis, while time after PLX5622 (or control) is represented on the x-axis in weeks. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0085] FIG. 7G shows Average daily food intake of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Average food intake as measured in grams per day (g / day) is represented on the y-axis, while treatment condition is represented on the x-axis. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0086] FIG. 7H shows Glucose tolerance test after 6 weeks PLX treatment of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Blood glucose concentration (mg / dL) is represented on the y-axis, while time in minutes (min) after glucose injection is represented on the x-axis. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0087] FIG. 8A-8G show Tissue weight and serum biomarkers in young Magel2-null mice after 11 weeks PLX5622 treatment. Data are means ± SEM. Sample size: n=4 WT / PLX (-), n=3 Magel2-null / PLX (-), n=4 Magel2-null / PLX (+). * P<0.05, ** P<0.01, # P=0.063.
[0088] FIG. 8A shows Tissue weight of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Tissue weight as measured in grams (g) is represented on the y-axis for different tissues represented on the x-axis. BAT, brown adipose tissue; iWAT, inguinal white adipose tissue; gWAT, gonadal white adipose tissue; rWAT, retroperitoneal white adipose tissue.
[0089] FIG. 8B shows Relative tissue weight (percentage of body weight) of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Relative tissue weight, measured as percent of baseline (% BW), is represented on the y-axis for different tissues represented on the x-axis. BAT, brown adipose tissue; iWAT, inguinal white adipose tissue; gWAT, gonadal white adipose tissue; rWAT, retroperitoneal white adipose tissue.
[0090] FIG. 8C shows Serum leptin of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Serum leptin as measured in ng / mL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0091] FIG. 8D shows Serum insulin of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Serum insulin as measured in ng / mL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.Docket No. 103362-109W01
[0092] FIG. 8E shows Serum glucose of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Serum glucose as measured in mg / dL is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0093] FIG. 8F shows insulin resistance of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). HOMA-IR is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0094] FIG. 8G shows Serum free fatty acid of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Serum free fatty acid as measured in pM is represented on the y-axis, while treatment groups PLX5622 (PLX (+)) or control (PLX (-)) are represented on the x-axis.
[0095] FIG. 9A-9D show Hypothalamic alterations in young Magel2-null mice after 11 weeks PLX5622 treatment. Data are means ± SEM. Sample size: n=4 WT / PLX (-), n=3 Magel2-null / PLX (-), n=4 Magel2-null / PLX (+). * P<0.05, ** P<0.01, *** PO.OOl, **** PO.OOOl.
[0096] FIG. 9A shows Relative expression of microglia-related genes. Relative mRNA levels are shown on the y-axis for different microglia-related genes represented on the x-axis.
[0097] FIG. 9B shows Relative expression of genes involved in energy balance regulation. Relative mRNA levels are shown on the y-axis for different genes involved in energy balance regulation represented on the x-axis.
[0098] FIG. 9C shows Western blotting of Ibal and Vinculin for mice administered PLX5622 (PLX (+)) compared to control (PLX (-)). Vinculin is included as a loading control. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0099] FIG. 9D shows Quantification of Western blotting in FIG. 9C. The ratio of Ibal to Vinculin band intensity is represented on the y-axis by arbitrary units for the treatment groups PLX5622 (PLX (+)) or control (PLX (-)) represented on the x-axis. Wild-type mice not receiving PLX5622 (WT / PLX (-)) are also included as a further control.
[0100] FIG. 10A-10D show Liver alterations in young Magel2-null mice after 11 weeks PLX5622 treatment. Data are means ± SEM. Sample size: n=4 WT / PLX (-), n=3 Magel2-null / PLX (-), n=4 Magel2-null / PLX (+). * P<0.05, ** P<0.01.
[0101] FIG. 10A-10B show Relative gene expression. Relative mRNA levels are shown on the y-axis for different genes represented on the x-axis.
[0102] FIG. 10C shows Western blotting for FASN, SREBP1, and PKCepsilon of Magel2-null mice receiving PLX5622 (PLX (+)) or control (PLX (-)). Beta-actin is included as a loading control.
[0103] FIG. 10D shows Quantification of Western blotting in FIG. 10C. The ratio of FASN, SREBP1, or PKCepsilon to corresponding Beta- Actin band intensity is represented on the y-Docket No. 103362-109W01
[0104] axis by arbitrary units for the treatment groups PLX5622 (PLX (+)) or control (PLX (-)) represented on the x-axis.
[0105] FIG. 11A-11F shows PLX5622 treatment affects body weight and food intake in middle-aged mice. Data are means ± SEM. n=6 WT / PLX (-), n=6 WT / PLX (+), n=5 Magel2-null / PLX (-), n=6 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Tukey’s post hoc test. * P<0.05, ** P<0.01, *** PO.OOl, **** p<0.0001, ns not significant.
[0106] FIG. 11 A shows body weight.
[0107] FIG. 11B shows body weight area under curve.
[0108] FIG. 11C shows body weight change (Percentage of baseline).
[0109] FIG. 11D shows weight change area under curve.
[0110] FIG. HE shows total weight change after 7-weeks PLX treatment.
[0111] FIG. 1 IF shows average daily food intake from week 1 to week 6 on PLX treatment. FIG. 12A-12B show PLX5622 treatment improves glucose tolerance in middle-aged Magel2-null mice. Data are means ± SEM. n=6 WT / PLX (-), n=6 WT / PLX (+), n=5 Magel2-null / PLX (-), n=6 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Fisher’s LSD post hoc test. * P<0.05, **** P<0.0001, ns not significant.
[0112] FIG. 12A shows glucose tolerance test after 6 weeks PLX treatment.
[0113] FIG. 12B shows glucose tolerance area under curve.
[0114] FIG. 13A-13F show tissue weight in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=6 WT / PLX (+), n=5 Magel2-null / PLX (-), n=6 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. * P<0.05, ** P<0.01, **** PO.OOOl, ns not significant.
[0115] FIG. 13A shows brown adipose tissue weight.
[0116] FIG. 13B shows inguinal white adipose tissue weight.
[0117] FIG. 13C shows gonadal white adipose tissue weight.
[0118] FIG. 13D shows retroperitoneal white adipose tissue weight.
[0119] FIG. 13E shows liver weight.
[0120] FIG. 13F shows spleen weight.
[0121] FIG. 14A-14D show serum biomarkers in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=6 WT / PLX (+), n=5 Magel2-null / PLX (-), n=6 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAsDocket No. 103362-109W01
[0122] (genotype x PLX) with Turkey’s post hoc test. * PO.05, ** PO.Ol, **** P0.0001, ns not significant.
[0123] FIG. 14A shows serum glucose.
[0124] FIG. 14B shows serum insulin.
[0125] FIG 14C shows HOMA-IR.
[0126] FIG. 14D shows serum leptin.
[0127] FIG. 15 shows Hypothalamic gene expression in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. * PO.05, ** PO.Ol, **** po.OOOl, ns not significant, trending P value shown where applied.
[0128] FIG. 16A-16B show hypothalamic Western blotting in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Unpaired t test. * P .05.
[0129] FIG. 16A shows Western blotting.
[0130] FIG. 16B shows quantification of Western blotting.
[0131] FIG. 17 shows hepatic gene expression of macrophage and inflammatory genes in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. * PO.05, ** PO.Ol, *** PO.OOl, **** P0.0001, ns not significant.
[0132] FIG. 18 shows hepatic expression of genes involved in lipogenesis and gluconeogenesis in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test or Fisher’s LSD post hoc test upon significant interaction. * PO.05, ** PO.Ol, *** PO.OOl, ns not significant, trending P value shown where applied.
[0133] FIG. 19A-19C show liver Western blotting in middle-aged Magel2-null mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Unpaired t test. * PO.05.
[0134] FIG. 19A shows Western blotting.
[0135] FIG. 19B shows quantification of Western blotting.
[0136] FIG. 19C shows Liver triglyceride level.
[0137] FIG. 20A-20F show relative tissue weight in middle-aged mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=5 WT / PLX (+), n=4 Magel2-null / PLX (-), n=5 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. * PO.05, ** PO.Ol, *** PO.OOl, **** P0.0001, ns not significant.Docket No. 103362-109W01
[0138] FIG. 20A shows relative brown adipose tissue weight (percentage of body weight). FIG. 20B shows relative inguinal white adipose tissue weight (percentage of body weight).
[0139] FIG. 20C shows relative gonadal white adipose tissue weight (percentage of body weight).
[0140] FIG. 20D shows relative retroperitoneal white adipose tissue weight (percentage of body weight).
[0141] FIG. 20E shows relative liver weight (percentage of body weight).
[0142] FIG. 20F shows relative spleen weight (percentage of body weight).
[0143] FIG. 21A-21F show PLX5622 treatment affects body weight and food intake in young adult mice. Data are means ± SEM. n=6 WT / PLX (-), n=5 WT / PLX (+), n=4 Magel2-null / PLX (-), n=5 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Tukey’s post hoc test. * P .05, ** P<0.01, **** PO.OOOl, ns not significant.
[0144] FIG. 21A shows body weight.
[0145] FIG. 2 IB shows body weight area under curve.
[0146] FIG. 21C shows body weight change (Percentage of baseline).
[0147] FIG. 2 ID shows weight change area under curve.
[0148] FIG. 2 IE shows total weight change after 7-weeks PLX treatment.
[0149] FIG. 2 IF shows average daily food intake from week 1 to week 6 post PLX treatment. FIG. 22A-22B show glucose tolerance in young adult mice after 6 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=5 WT / PLX (+), n=4 Magel2-null / PLX (-), n=5 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Tukey’s post hoc test, ns not significant.
[0150] FIG. 22A shows glucose tolerance.
[0151] FIG. 22B shows glucose tolerance area under curve.
[0152] FIG. 23A-23F show tissue weight in young adult mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=5 WT / PLX (+), n=4 Magel2-null / PLX (-), n=5 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. * PO.05, ** P<0.01, **** PO.OOOl, ns not significant.
[0153] FIG. 23A shows brown adipose tissue weight.
[0154] FIG. 23B shows inguinal white adipose tissue weight.
[0155] FIG. 23C shows gonadal white adipose tissue weight.Docket No. 103362-109W01
[0156] FIG. 23D shows retroperitoneal white adipose tissue weight.
[0157] FIG. 23E shows liver weight.
[0158] FIG. 23F shows spleen weight.
[0159] FIG. 24A-24D show serum biomarkers in young adult mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=6 WT / PLX (-), n=5 WT / PLX (+), n=4 Magel2-null / PLX (-), n=5 Magel2-null / PLX (+). Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. **** PO.OOOl, ns not significant.
[0160] FIG. 24A shows serum glucose.
[0161] FIG. 24B shows serum insulin.
[0162] FIG 24C shows HOMA-IR.
[0163] FIG. 24D shows serum leptin.
[0164] FIG. 25 shows downregulation of hypothalamic gene expression of microglia markers in young adult mice after 7 weeks PLX5622 treatment. Data are means ± SEM. n=5 per group. Individual values are shown in graph. Two-way ANOVAs (genotype x PLX) with Turkey’s post hoc test. ** PO.Ol, *** PO.OOl, **** PO.OOOl, ns not significant.
[0165] DETAILED DESCRIPTION
[0166] The following description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known embodiment(s). To this end, those skilled in the relevant art will recognize and appreciate that many changes can be made to the various embodiments of the invention described herein, while still obtaining the beneficial results of the present disclosure. It will also be apparent that some of the desired benefits of the present disclosure can be obtained by selecting some of the features of the present disclosure without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the present disclosure are possible and can even be desirable in certain circumstances and are a part of the present disclosure. Thus, the following description is provided as illustrative of the principles of the present disclosure and not in limitation thereof.
[0167] Reference will now be made in detail to the embodiments of the invention, examples of which are illustrated in the drawings and the examples. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[0168] DefinitionsDocket No. 103362-109W01
[0169] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.
[0170] As used in the specification and claims, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.
[0171] As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation "may include an excipient" is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
[0172] “Administration" to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrastemal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like. "Concurrent administration", "administration in combination", "simultaneous administration" or "administered simultaneously" as used herein, means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time. "Systemic administration" refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems. By contrast, "local administration" refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount. For example, locally administered agents are easily detectable in the local vicinity of the point of administration butDocket No. 103362-109W01
[0173] are undetectable or detectable at negligible amounts in distal parts of the subject's body. Administration includes self-administration and the administration by another.
[0174] As used here, the terms “therapeutic agent,” “beneficial agent,” and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like. When the terms “beneficial agent” or “active agent” are used, then, or when a particular agent is specifically identified, it is to be understood that the term includes the agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, conjugates, active metabolites, isomers, fragments, analogs, etc.
[0175] As used herein, the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and / or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.
[0176] As used herein, the terms “treating” or “treatment” of a subject includes the administration of a drug to a subject with the purpose of curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder. The terms “treating” and “treatment” can also refer to reduction in severity and / or frequency of symptoms, elimination of symptoms and / or underlying cause, prevention of the occurrence of symptoms and / or their underlying cause, and improvement or remediation of damage.
[0177] By the term “effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect. The amount of beneficial agent that is “effective” will vary from subject to subject, depending on the age and general condition of the subject, the particular beneficial agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount”. However, an appropriate “effective’ amount in any subject case may be determined by one of ordinary skill in the art using routine experimentation. Also, as used herein, and unless specifically stated otherwise, an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.Docket No. 103362-109W01
[0178] An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
[0179] As used herein, a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result, and a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition. Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject. The term “therapeutically effective amount" can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect. The precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and / or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
[0180] As used herein, the term “pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. When the term “pharmaceutically acceptable" is used to refer to an excipient, it is generally implied that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
[0181] "Pharmaceutically acceptable carrier" (sometimes referred to as a "carrier") means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and / or human pharmaceutical or therapeutic use. The terms "carrier" or "pharmaceutically acceptable carrier" can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil / water or water / oil emulsion) and / or various types of wetting agents. As used herein, the term "carrier" encompasses, but is not limited to, any excipient, diluent, filler, salt,Docket No. 103362-109W01
[0182] buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
[0183] As used herein, “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, nontoxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.
[0184] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)n- COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
[0185] Also, as used herein, the term “pharmacologically active” (or simply “active”), as in a “pharmacologically active” derivative or analog, can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
[0186] As used herein, the term “subject” or “host” can refer to living organisms such as mammals, including, but not limited to humans, livestock, dogs, cats, and other mammals.Docket No. 103362-109W01
[0187] Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject. In some embodiments, the subject is a human.
[0188] As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a mixture containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the mixture.
[0189] A weight percent (wt.%) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
[0190] Methods
[0191] In one aspect, provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating Prader-Willi Syndrome (PWS) in a subject in need thereof, comprising administering to the subject an inhibitor of colony stimulating factor 1 receptor (CSF1R).
[0192] In some embodiments, the CSF1R inhibitor depletes microglia. In some embodiments, the CSF1R inhibitor depletes macrophages. In some embodiments, the CSF1R inhibitor depletes liver macrophages.
[0193] In some embodiments, the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
[0194] In some embodiments, the CSF1R inhibitor is an antibody or a derivative thereof. Anti- CSF1R antibodies suitable for the present invention are known in the prior art. Suitable anti- CSF1R antibodies are for instance also commercially available from Santa Cruz Biotechnology Inc. (Dallas, TX, USA), ThermoFisher, or Abeam (Cambridge, UK).
[0195] In some embodiments, the CSF1R inhibitor comprises the M279 rat monoclonal antibody or a derivative thereof (MacDonald, K.P. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associatedDocket No. 103362-109W01
[0196] macrophages but does not inhibit inflammation. Blood. 2010 Nov 11; 116(19):3955-63, incorporated herein by reference).
[0197] In some embodiments, the CSF1R inhibitor comprises the AFS98 rat monoclonal antibody or a derivative thereof (Sudo, T. et al. Functional hierearchy of c-kit and c-fins in intramarrow production of CFU-M., Oncogene, 1995, vol. 1112(pg. 2469-2479). incorporated herein by reference).
[0198] For example, a monoclonal antibody specific to human CSF1R can be selected from or derived from Clone D-8 (Santa Cruz, Cat # sc-365719), Clone B-8 (Santa Cruz, Cat # sc-46662).
[0199] In another example, a monoclonal antibody specific to human CSF1R can be selected from or derived from CD115 (12-3A3-1B10) (eBioscience™, Cat # 14-1159-82), Clone 6C7 (ThermoFisher, Cat # BSM-51303M), or CD115 (c-fms) (04) (ThermoFisher, Cat # MAS-35980).
[0200] In another example, a monoclonal antibody specific to human CSF1R can be selected from or derived from EPR21885-161 (Abeam, Cat # ab221684), EPR28407-22 (Abeam, Cat # ab313648), EPR20754 (Abeam, Cat # ab229188), RM2042 (Abeam, Cat # ab315490), EPR20634(Abcam, Cat # ab239079), or EPR28407-22 (Abeam, Cat # ab313649).
[0201] In some embodiments, the anti-CSFIR antibody is a monoclonal antibody. The monoclonal anti-CSFIR antibody is preferably humanized. Methods to obtain humanized antibodies are well known in the art.
[0202] In some embodiments, the CSF1R inhibitor comprises siRNA. Methods of RNA interference comprising administering CSF1R siRNA are disclosed in, for example, Bencheikh, L. et al. Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages. Nat Commun 10, 1935 (2019), incorporated herein by reference.
[0203] Anti-CSFIR receptor siRNA suitable for the present invention are known in the prior art. Suitable anti-CSFIR siRNA are for instance also commercially available from ThermoFisher and Qiagen. In some embodiments, the anti-CSFIR siRNA is derived or selected from one or more of ThermoFisher Assay ID 146601, Catalog # AM16708; ThermoFisher Assay ID 146602, Catalog # AM16708; ThermoFisher Assay ID 146603, Catalog # AM16708; ThermoFisher Assay ID 641, Catalog # AM16708; ThermoFisher Assay ID 642, Catalog # AM16708; ThermoFisher Assay ID 643, Catalog # AM16708; ThermoFisher Assay ID HSS102358, Catalog # 1299001; ThermoFisher Assay ID HSS102359, Catalog # 1299001; ThermoFisher Assay ID HSS102360, Catalog # 1299001; ThermoFisher Assay ID n302432,Docket No. 103362-109W01
[0204] Catalog # 4390771; ThermoFisher Assay ID s3594, Catalog # 4392420; ThermoFisher Assay ID s3595, Catalog # 4392420; or ThermoFisher Assay ID s3596, Catalog # 4392420.
[0205] In some embodiments, the CSF1R inhibitor is a small molecule. In some embodiments, the CSF1R inhibitor is selected from Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl) oxy]-2-methoxyphenyl}-N’-[l-(l,3-thiazole-2-yl)ethyl] urea); JNJ28312141 (4-cyano- N-[2-(l-cyclohexen-l-yl)-4-[l -[(dimethylamino) acetyl] -4-piperidinyl] phenyl]- 1 H-imidazole-2-carboxamide); JNJ40346527 (5-cyano-N-[2-(4,4- dimethylcyclohex- 1 -en-1 -yl)-6-(2, 2,6,6-tetramethyloxan-4-yl) pyridin-3-yl]-l H- imidazole-2-carboxamide); PLX3397 (5-((5-chloro-1 H-pyrrolo[2,3-b] pyridin-3- yl)methyl)-N-((6-(trifluoromethyl) pyridin-3-yl)methyl)pyridin-2-amine (Pexidartinib, CAS 1029044-16-3)); PLX5622 (6-fluoro-N-((5-fluoro-2-methoxypyridin-3-yl)methyl)-5-((5-methyl-l H-pyrrolo[2,3-b]pyridin-3-yl)methyl)pyridin-2-amine); Plx647 (5-(l H-pyrrolo[2,3-b] pyridin-3 -ylmethyl)- N-[[4- (trifluoromethyl)phenyl]methyl]-2-pyridinamine (CAS 873786-09-5)); TPX-0022, NMS-03592088 (NMS P088), DCC-3014; GW-2580 (5-[3- Methoxy-4-(4-methoxybenzyloxy) benzyl] pyrimidine-2, 4-diamine); BLZ945 (4-[[2-[[(l R,2R)-2 -hydroxy cyclohexyl] amino]-6-benzothiazolyl] oxy]-N-methyl- 2-pyridinecarboxamide (CAS 953769-46-5)); CS2164 (N-(2-aminophenyl)-6- [(7-methoxy-4-quinolinyl)oxy] - 1 -naphthalenecarboxamide (Chiauranib)); ARRY-382 (6-[5-[[[2-(methylsulfonyl)ethyl]amino] methyl]-2-furanyl]-N-[3- methyl-4-([l ,2,4]triazolo[l ,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine); N- (4-([l,2,4]triazolo[l ,5-a]pyridin-7-yloxy)-3-methylphenyl)-6-(5-(((2- (methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine (ARRY-382 analog CAS No. : 937265-83-3); N-{4-[(6,7-Dimethoxy-4-quinolyl) oxy]-2- methoxyphenyl}-N'-[(lS)-l-(4-fluorophenyl) ethyl] urea; N-{4-[(6,7-Dimethoxy- 4-quinolyl) oxy]-2-methoxyphenyl}-N'-[l -(1 ,3-thiazol-2-yl)ethyl]urea; N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[(l S)-l -(1 ,3-thiazol-2-yl)ethyl]urea; N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'- [(1 R)-l -(1 ,3-thiazol-2-yl)ethyl]urea; N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]-3- methoxyphenyl}-N'-[l -(1 ,3-thiazol-2-yl)ethyl]urea; N-{4-[(6,7-Dimethoxy-4- quinolyl)oxy ] -3 -methoxy phenyl }-N'-[(l S)-l -(1 ,3-thiazol-2-yl)ethyl]urea; N-{4- [(6,7-Dimethoxy-4-quinolyl)oxy]-3-methoxyphenyl}-N'-[(l R)-l -(1 ,3-thiazol-2- yl)ethyl]urea; and N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2-(trifluoromethyl)phenyl]-N'-[(l S)-l -(1 ,3-thiazol-2-yl)ethyl]urea; or a solvate, hydrate, tautomer, enantiomer, prodrug, or pharmaceutically acceptable salt thereof.
[0206] In some embodiments, the CSF1R inhibitor is selected from ARRY-382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622,Docket No. 103362-109W01
[0207] PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
[0208] In some embodiments, the CSF1R inhibitor is PLX5622, or a pharmaceutically acceptable salt thereof. The structure of PLX5622 is shown below:
[0209]
[0210] In some embodiments, the CSF1R inhibitor is formulated in or with lipid nanoparticles (LNP), polymeric nanoparticles (PNP), liposomes, viral drug delivery systems, exosomes, or a combination thereof. In some embodiments, the liposomes comprise clodronate liposomes.
[0211] In some embodiments, the method further comprises administering to the subject a growth hormone therapy.
[0212] In some embodiments, the method further comprises administering to the subject a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0213] In another aspect, provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof.
[0214] In some embodiments, PLX5622 is administered orally.
[0215] In some embodiments, PLX5622 is administered at a dose between about 10 mg and about 2500 mg, for example about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 175 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 225 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 275 mg, about 280 mg, about 290 mg, about 300 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg,Docket No. 103362-109W01
[0216] about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg. In some embodiments, PLX5622 is orally administered at a dose selected from about 200 mg, about 400 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1400 mg, or about 1600 mg.
[0217] In some embodiments, PLX5622 is administered at least once per day. In some embodiments, PLX5622 is administered at least twice per day. In some embodiments, PLX5622 is administered at least three times per day.
[0218] In some embodiments, PLX5622 is administered at least once per day for at least 7 days. In some embodiments, PLX5622 is administered at least once per day for at least 14 days. In some embodiments, PLX5622 is administered at least once per day for at least 21 days.
[0219] In some embodiments, PLX5622 is administered in one or more cycles, comprising an on period comprising administration of PLX5622 followed by an off period comprising no administration of PLX5622. In some embodiments, the on period lasts 7 days, 14 days, 21 days, 28 days, 35 days, or more. In some embodiments, the off period lasts 7 days, 14 days, 21 days, 28 days, 35 days, 3 months, 6 months, 9 months, one year, or more. In some embodiments, the cycle is repeated at least 2 times, at least 3 times, at least 4 times, or more than 4 times.
[0220] In some embodiments, the method further comprises administering to the subject a growth hormone therapy.
[0221] In some embodiments, the method further comprises administering to the subject a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0222] In one aspect, provided herein is a method for treating one or more symptoms associated with PWS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof. In some embodiments, the one or more symptoms are selected from increased body weight, increased fat mass, decreased lean mass, increased food intake, worsened glucose tolerance, or a combination thereof.
[0223] As used herein, "treating a symptom" of PWS is ameliorating any condition or symptom associated with the of a PWS. As compared with an equivalent untreated control, such reduction is by at least 5%, for example at least about 10%, at least about 20%, at least about 40%, at least about 50%, at least about 60%, at least about 80%, at least about 90%, at leastDocket No. 103362-109W01
[0224] about 95%, at least about 99%, or more than about 99%, as measured by any standard technique.
[0225] In an alternative aspect, provided herein is a method for reducing body weight in a subject having PWS, comprising administering to the subject a CSF1R inhibitor. In some embodiments, the body weight of the subject is reduced by at least about 3%, for example at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, or more than about 10%.
[0226] In an alternative aspect, provided herein is a method for decreasing fat mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor. In some embodiments, the fat mass of the subject is decreased by at least about 3%, for example at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, or more than about 10%.
[0227] In an alternative aspect, provided herein is a method for increasing lean mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor. In some embodiments, the lean mass of the subject is increased by at least about 3%, for example at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, or more than about 10%.
[0228] In an alternative aspect, provided herein is a method for decreasing food intake in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0229] In some embodiments, the food intake of the subject is reduced by at least about 200 calories per day, for example at least about 225 calories per day, at least about 250 calories per day, at least about 275 calories per day, at least about 300 calories per day, at least about 350 calories per day, at least about 400 calories per day, at least about 450 calories per day, at least about 500 calories per day, at least about 750 calories per day, at least about 1000 calories per day, or more than about 1000 calories per day.
[0230] In an alternative aspect, provided herein is a method for improving glucose tolerance in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0231] In an alternative aspect, provided herein is a method for decreasing free fatty acid levels in a subject having PWS, comprising administering to the subject a CSF1R inhibitor. In some embodiments, the free fatty acid levels of the subject are decreased by at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, or more than about 10%.
[0232] In an alternative aspect, provided herein is a method for treating a subject with PWS having a body mass index (BMI) of equal to or greater than about 27.5, comprisingDocket No. 103362-109W01
[0233] administering to the subject a therapeutically effective amount of a CSF1R inhibitor as described herein.
[0234] In another aspect, provided herein is a method for treating a subject with PWS having a BMI of equal to or greater than about 30, comprising administering to the subject a therapeutically effective amount of a CSF1R inhibitor as described herein.
[0235] In another aspect, provided herein is a method for treating a subject with PWS having a BMI of equal to or greater than about 35, comprising administering to the subject a therapeutically effective amount of a CSF1R inhibitor as described herein.
[0236] In another aspect, provided herein is a method for treating a subject with PWS having a BMI of equal to or greater than about 40, comprising administering to the subject a therapeutically effective amount of a CSF1R inhibitor as described herein.
[0237] In yet another alternative aspect, provided herein is a method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising: (i) obtaining a sample from the subject; (ii) measuring the expression level of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC, or a combination thereof, in the sample compared to a control; and (iii) if the levels of one or more of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC are elevated compared to control, then administering to the subject a therapeutically effective amount of a CSF1R inhibitor as described herein.
[0238] In some embodiments, one or more, two or more, three or more, or four or more of the expression levels of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC are elevated in the sample compared to control.
[0239] In some embodiments, the sample comprises a tissue sample. In some embodiments, the sample comprises a biofluid. In some embodiments, the biofluid comprises blood. In some embodiments, the biofluid comprises urine. In some embodiments, the biofluid comprises cerebrospinal fluid.
[0240] In some embodiments, the mRNA expression level of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC, or a combination thereof, is assayed. In some embodiments, mRNA expression levels are measured using next generation sequencing. Next generation sequencing and methods of using thereof to assay mRNA expression levels are known to those of skill in the art. In some embodiments, the protein expression level of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC, or a combination thereof, is assayed. In some embodiments, protein expression levels are measured using proteomics. Mass spectrometry-based proteomics and methods of using thereof to assay protein expression levels are known to those of skill in the art.Docket No. 103362-109W01
[0241] In some embodiments, the CSF1R inhibitor depletes microglia. In some embodiments, the CSF1R inhibitor depletes macrophages. In some embodiments, the CSF1R inhibitor depletes liver macrophages.
[0242] In some embodiments, the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
[0243] In some embodiments, the CSF1R inhibitor is selected from ARRY-382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof. In some embodiments, the CSF1R inhibitor is PLX5622.
[0244] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent. In some embodiments, the additional therapeutic agent comprises a pre- / pro-biotic dietary supplement, a growth hormone therapy, a cannabidiol, or a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the additional therapeutic agent is selected from melanotan II (MT-II), setmelanotide, Pitolisant, VYKAT XR, CSTI-500, NNZ-2591, RGH-706, oxytocin, diazoxide choline (DCCR), BMB-101, ARD-101, carbetocin, RAD011, tesomet, GLWL-01, exenatide, topiramate, octreotide, rimonabant, livoletide (AZP-531), beloranib (ZGN-440), carbetocin, somatropin, anastrozole, RM-718, tirzepatide, liraglutide, or Coenzyme Q10.
[0245] In some embodiments, the method further comprises administering to the subject a growth hormone therapy. In some embodiments, the growth hormone therapy comprises a Recombinant Human Growth Hormone (rhGH) injection. In some embodiments, the growth hormone therapy comprises Norditropin SimpleXx. In some embodiments, the growth hormone therapy comprises somatropin injection. In some embodiments, the growth hormone therapy comprises eutropin or genotropin.
[0246] In some embodiments, the method further comprises administering to the subject a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0247] In some embodiments, the subject is an adult. In some embodiments, the subject is a child. In some embodiments, the subject is a human.
[0248] Pharmaceutical Compositions for UseDocket No. 103362-109W01
[0249] In any of the preceding aspects described herein, a pharmaceutical composition comprising a therapeutically effective amount of a CSF1R inhibitor, and a pharmaceutically acceptable carrier, is administered to the subject in need thereof.
[0250] In one aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a CSF1R inhibitor for use in preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject.
[0251] In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof, for use in preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject.
[0252] Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., fdms, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
[0253] Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.
[0254] Carriers or excipients can be used to produce compositions. The carriers or excipients can be chosen to facilitate administration of the compound. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. Examples of physiologically compatible solvents include sterile solutions of water for injection (WFI), saline solution, and dextrose.
[0255] Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.Docket No. 103362-109W01
[0256] Pharmaceutical compositions for use may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.
[0257] The pharmaceutical composition for use may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. Dosage forms may also in part depend upon the use or the route of administration, for example, oral, transdermal, transmucosal, inhalant, or by injection (parenteral).
[0258] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
[0259] Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
[0260] Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.
[0261] Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanol amines.Docket No. 103362-109W01
[0262] In some embodiments, the compounds as described herein are prepared in additional forms, such as polymorphs, salt forms, and complexes. In some embodiments, the additional forms can improve the biopharmaceutical properties, and can be further formulated to enhance biopharmaceutical properties. In some embodiments, compounds as described herein can form complexes that are substantially or partially amorphous. In some embodiments, the amorphous complexes can be combined with a polymer, including but not limited to HPMCAS, which can further stabilize the amorphous form. In some embodiments, the stabilized amorphous complex can be spray dried to provide a dried complex.
[0263] In some embodiments, the CSF1R inhibitor compounds according to the methods of the present disclosure are used in combination with other therapies for treating PWS. Such combination use includes administration of the compounds and one or more other therapeutics at different times, or co-administration of the compound and one or more other therapies. In some embodiments, dosage may be modified for one or more of the compounds of the disclosure or other therapeutics used in combination, e.g., reduction in the amount dosed relative to a compound or therapy used alone, by methods well known to those of ordinary skill in the art.
[0264] In some embodiments, the therapeutically effective amount of a CSF1R inhibitor used in the methods provided herein is about 10 mg per day (mg / day), for example about 50 mg / day, about 90 mg / day, about 100 mg / day, about 135 mg / day, about 150 mg / day, about 200 mg / day, about 250 mg / day, about 300 mg / day, about 350 mg / day, about 400 mg / day, about 450 mg / day, about 500 mg / day, about 600 mg / day, about 700 mg / day, about 800 mg / day, about 900 mg / day, about 1000 mg / day, about 1200 mg / day, about 1300 mg / day, about 1400 mg / day, about 1500 mg / day, about 1600 mg / day, about 1700 mg / day, about 1800 mg / day, about 1900 mg / day, about 2000 mg / day, about 2200 mg / day, about 2500 mg / day, about 3000 mg / day, about 3500 mg / day, about 4000 mg / day, about 4500 mg / day, about 5000 mg / day, or more than about 5000 mg / day. In certain embodiments, the compound is administered continuously.
[0265] In some embodiments, the CSF1R inhibitor is PLX5622, or a pharmaceutically acceptable salt thereof.
[0266] In some embodiments, the therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof, used in the methods provided herein is at least about 10 mg per day (mg / day). In some embodiments, the therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof, used in the methods provided herein is between about 10 mg / day and about 2500 mg / day. In certain embodiments, the therapeutically effective amount is about 10 mg / dosage, about 50 mg / dosage, about 90Docket No. 103362-109W01
[0267] mg / dosage, about 100 mg / dosage, about 135 mg / dosage, about 150 mg / dosage, about 200 mg / dosage, about 250 mg / dosage, about 300 mg / dosage, about 350 mg / dosage, about 400 mg / dosage, about 450 mg / dosage, about 500 mg / dosage, about 600 mg / dosage, about 700 mg / dosage, about 800 mg / dosage, about 900 mg / dosage, about 1000 mg / dosage, about 1200 mg / dosage, about 1300 mg / dosage, about 1400 mg / dosage, about 1500 mg / dosage, about 1600 mg / dosage, about 1700 mg / dosage, about 1800 mg / dosage, about 1900 mg / dosage, about 2000 mg / dosage, about 2100 mg / dosage, about 2200 mg / dosage, about 2300 mg / dosage, about 2400 mg / dosage, or about 2500 mg / dosage.
[0268] EMBODIMENTS
[0269] 1. A method for preventing or treating Prader-Willi Syndrome (PWS) in a subject in need thereof, comprising administering to the subject an inhibitor of colony stimulating factor 1 receptor (CSF1R).
[0270] 2. The method of embodiment 1, wherein the CSF1R inhibitor depletes microglia.
[0271] 3. The method of embodiment 1 or 2, wherein the CSF1R inhibitor depletes macrophages.
[0272] 4. The method of any of embodiments 1-3, wherein the CSF1R inhibitor depletes liver macrophages.
[0273] 5. The method of any of embodiments 1-4, wherein the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
[0274] 6. The method of any of embodiments 1-4, wherein the CSF1R inhibitor is selected from ARRY-382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
[0275] 7. The method of any of embodiments 1-4, wherein the CSF1R inhibitor is PLX5622, or a pharmaceutically acceptable salt thereof.
[0276] 8. The method of any of embodiments 1 -7, further comprising administering to the subj ect a growth hormone therapy.Docket No. 103362-109W01
[0277] 9. The method of any of embodiments 1 -8, further comprising administering to the subj ect a melanocortin 4 receptor (MC4R) agonist.
[0278] 10. The method of embodiment 9, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0279] 11. A method for preventing or treating PWS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof.
[0280] 12. The method of embodiment 11, wherein PLX5622 is administered orally.
[0281] 13. The method of embodiment 11 or 12, wherein PLX5622 is administered at a dose between about 10 mg and about 2500 mg.
[0282] 14. The method of embodiment 11 or 12, wherein PLX5622 is orally administered at a dose selected from about 200 mg, about 400 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1400 mg, or about 1600 mg.
[0283] 15. The method of any of embodiments 11-14, wherein PLX5622 is administered at least once per day.
[0284] 16. The method of any of embodiments 11-15, wherein PLX5622 is administered for at least 14 days.
[0285] 17. The method of any of embodiments 11-16, further comprising administering to the subject a growth hormone therapy.
[0286] 18. The method of any of embodiments 11-17, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
[0287] 19. The method of embodiment 18, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0288] 20. A method for reducing body weight in a subj ect having PWS, comprising administering to the subject a CSF1R inhibitor.
[0289] 21. A method for decreasing fat mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0290] 22. A method for increasing lean mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.Docket No. 103362-109W01
[0291] 23. A method for decreasing food intake in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0292] 24. A method for improving glucose tolerance in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0293] 25. A method for decreasing free fatty acid levels in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
[0294] 26. A method for preventing or treating PWS in a subject in need thereof, comprising:
[0295] (i) obtaining a sample from the subj ect;
[0296] (ii) measuring the expression level of FASN, SREBP1, PKCe, or G6PC, or a combination thereof, in the sample compared to a control; and
[0297] (iii) if the levels of one or more of FASN, SREBP1, PKCe, or G6PC are elevated compared to control, then administering to the subject a CSF1R inhibitor.
[0298] 27. The method of any of embodiments 20-26, wherein the CSF1R inhibitor depletes microglia.
[0299] 28. The method of any of embodiments 20-27, wherein the CSF1R inhibitor depletes macrophages.
[0300] 29. The method of any of embodiments 20-28, wherein the CSF1R inhibitor depletes liver macrophages.
[0301] 30. The method of any of embodiments 20-29, wherein the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
[0302] 31. The method of any of embodiments 20-29, wherein the CSF1R inhibitor is selected from ARRY-382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
[0303] 32. The method of any of embodiments 20-29, wherein the CSF1R inhibitor is PLX5622.
[0304] 33. The method of any of embodiments 20-32, further comprising administering to the subject a growth hormone therapy.Docket No. 103362-109W01
[0305] 34. The method of any of embodiments 20-33, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
[0306] 35. The method of embodiment 34, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
[0307] EXAMPLES
[0308] The following examples are set forth below to illustrate the compositions, devices, methods, and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art.
[0309] Example 1. CSF1R inhibitor PLX5622 improves metabolic function in middle-aged Magel2-null mouse model of Prader-Willi syndrome
[0310] It was hypothesized that hypothalamic microglia may play a role in the metabolic dysfunction in Magel2 deficiency and thereby a potential therapeutic target. In this study, PLX5622, a highly potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), was used to pharmacologically deplete microglia and assess whether microglia depletion could ameliorate the metabolic disturbance in Magel2-null mice.
[0311] Materials and Methods
[0312] Mice
[0313] Magel2-null mice harbor a maternally -inherited imprinted / silenced wild type allele and a paternally-inherited Magel2-lacZ knock-in allele that abolishes endogenous Magel2 gene function. Male mice containing the Magel2-lacZ allele (Jackson Labs #009062, RRID:IMSR_J AX: 009062) on C57BL / 6J strain were bred with female C57BL / 6J mice to produce both wild type mice and Magel2-null littermates. Mice were genotyped from ear notch biopsies. Identification of mutant offspring was performed by polymerase chain reaction genotyping with Magel2 and LacZ oligonucleotide primers (common forward, 5'-ATGGCTCCATCAGGAGAAC (SEQ ID NO: 103); Magel2 reverse, 5'-GATGGAAAGACCCTTGAGGT (SEQ ID NO: 104); and LacZ reverse, RW4237, 5'-GGGATAGGTCACGTTGGTGT (SEQ ID NO: 105)). Genotype was further confirmed by qRT-PCR detecting Magel2 transcript in the hypothalamus. Mice were housed withinDocket No. 103362-109W01
[0314] temperature (22-23°C) and humidity (30-70%) controlled rooms under a 12: 12 light: dark cycle. All mice had ad libitum access to food and water. All animal experiments were in accordance with proper regulations.
[0315] PLX5622 treatment
[0316] CSF1R inhibitor PLX5622 was provided by Plexxikon, Inc. (Berkley, CA) and formulated at 1200 ppm into rodent diet AIN-76A (12% fat, caloric density 3.86kcal / g) by Research Diets, Inc. (New Brunswick, NJ). For middle aged cohort, female Magel2-null mice, approximately 10 months of age, were randomized to receive either the PLX5622 formulated diet or a normal chow diet (AIN-76A) for 7 weeks. For young adult cohort, female Magel2-null mice, 3 months of age, were randomized to receive either PLX5622 formulated diet or AIN-76A diet for 11 weeks. Sex and age-matched wildtype mice were fed with AIN-76A diet as a normal control.
[0317] Body composition assessment
[0318] Body composition was assessed with a 3-in-l Analyzer (EchoMRI LLC, Houston, TX) prior to initiation of PLX5622 treatment and at 4 weeks on PLX diet. Fat and lean mass were measured in live mice without anesthesia according to manufacturer instructions. Mice were subjected to a 5-Gauss magnetic field and whole-body masses of fat, lean, free water, and total water were determined during separate cycles by manufacturer software comparison to a canola oil standard.
[0319] Body weight and food intake measurement
[0320] Body weight was monitored weekly throughout the experiments. Food intake was recorded at the cage level on a weekly basis throughout the experiments. Average food intake was calculated on a per-mouse per-day basis excluding the data collected in weeks during which invasive procedures occurred (e.g., overnight fast for glucose tolerance test).
[0321] Glucose tolerance test
[0322] At 6 weeks on PLX treatment, mice were injected intraperitoneally with glucose solution (1.0 g glucose per kg body weight) after a 16 h overnight fast. Blood was obtained from the tail at 0, 15, 30, 60, 90, and 120 min after glucose injection. Blood glucose concentrations were measured with a portable glucose meter using default manufacturerDocket No. 103362-109W01
[0323] settings (Bayer Contour Next). Following blood collection, styptic powder was used to stop bleeding.
[0324] Tissue collection
[0325] The middle-aged cohort was euthanized after 7 weeks PLX treatment, and the young cohort was sacrificed after 11 weeks PLX treatment. Mice were anesthetized with 2.5% isoflurane (1.0 L / min) following a 4h fast and then decapitated to collect trunk blood. Hypothalamus was dissected under a dissection microscope, with the left and right side being collected separately to allow for RNA and protein isolation from each mouse. Fat pads including intrascapular brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), and retroperitoneal white adipose tissue (rWAT), liver, and spleen were collected and weighed. Tissues to be used for mRNA and protein analyses were flash frozen on dry ice and stored at -80°C until further analysis.
[0326] Serum harvest and analysis
[0327] Trunk blood was collected, clotted on ice, and centrifuged at 10,000 rpm for 10 min at 4°C. The serum component was harvested and stored at -20°C until further analysis. ELISAs were performed to assay serum leptin (R and D Systems Cat# DY498, RRID: AB 3668792) and serum insulin (Alpco Diagnostics Cat# 80-INSMSU-E01, RRID: AB_2792981). Caymen Chemical colorimetric assay kit was used to assay glucose (#10009582) and triglycerides (#10010303), and free fatty acids (#700310). HOMA-IR (homeostatic model assessment for insulin resistance) index was calculated as [fasting serum glucose (mmol / L) x fasting serum insulin (pmol / L) / 22.5] as described elsewhere.
[0328] Hepatic triglyceride quantification
[0329] Lipids were extracted from liver tissue by chloroform / methanol (2:1 v / v), followed by rinses in 50 mM NaCl and CaC12 (0.36M) / Methanol (1:1 v / v). Hepatic triglyceride was quantified with a Caymen Chemical triglyceride assay kit (#10010303).
[0330] Quantitative RT-PCR
[0331] Following tissue sonication, RNA was isolated using the QIAGEN RNeasy Mini kit (#74804). cDNA was reverse transcribed using Taqman Reverse Transcription ReagentsDocket No. 103362-109W01
[0332] (Applied Biosystems #N8080234). qRT-PCR was conducted on the StepOnePlus Real-Time PCR System using Power SYBR Green (Applied Biosystems #A25742) PCR Master Mix. Primer sequences are provided as SEQ ID NOs: 1-102. Data were calibrated to endogenous controls — Hprtl for hypothalamus, Actinb for adipose tissues, Ppia for liver. The relative gene expression was quantified using the 2-DDCT method.
[0333] Western blotting
[0334] Hypothalamus and liver tissues were homogenized in ice-cold RIPA buffer (Pierce #89901) containing lx PhosSTOP (Roche #4906845001) and protease inhibitor cocktail III (Calbiochem #539134). Tissues lysates were spun at 13,000 rpm for 15 min at 4 °C and the supernatant was collected. The protein concentration was determined with a BC A protein assay kit (Pierce). 15 pg protein from each sample was loaded and separated by gradient gel (4-20%, Mini-PROTEAN TGX, Bio-Rad), then transferred to a nitrocellulose membrane (BIO-RAD). Blots were incubated overnight at 4 °C with the following primary antibodies: Vinculin (Cell Signaling Technology Cat# 13901, RRID:AB_2728768, 1:1000), Ibal (FUJIFILM Wako Pure Chemical Corporation Cat# 016-20001, RRID:AB_839506, 1:500), Phospho- AKT-Ser473 (p-AKT, Cell Signaling Technology Cat# 9271, RRID:AB_329825, 1:600), total AKT (t-AKT, Cell Signaling Technology Cat# 9272, RRID:AB_329827, 1:1000), Fatty acid synthase (Cell Signaling Technology Cat# 3180, RRID:AB_2100796 , 1:1000), ChREBP (Cell Signaling Technology Cat# 58069, RRID:AB_2799539, 1:1000), SREBP1 (Novus Cat# NB100-2215, RRID:AB_10002406, 1:200), PKC-epsilon (Cell Signaling Technology Cat# 2683, RRID:AB_2171906, 1:1000), b-Actin (Cell Signaling Technology Cat# 4970, RRID:AB_2223172, 1:1000). Blots were rinsed and incubated with HRP -conjugated secondary antibodies (Bio-Rad, 1:3000). Chemiluminescence signal was detected and visualized by LI-COR Odyssey Fc imaging system (LI-COR Biotechnology, Lincoln, NE). Quantification analysis was carried out with Image Studio software version 5.2 (LI-COR Biotechnology).
[0335] Quantification and statistical analysis
[0336] Statistical analyses were performed using GraphPad Prism 10 software (GraphPad, San Diego, CA, USA). Unpaired t test with Welch’s correction was utilized for comparisons between two groups. One-way ANOVA with Tukey’s post hoc test was used for comparisons between three groups. Time course data (BWs, GTT) were analyzed using a mixed ANOVA. Normality was tested using the Shapiro-Wilk method. Significance was defined as P < 0.05.Docket No. 103362-109W01
[0337] Data are reported as means ± SEM. Sample sizes (n) can be found in each figure’s respective legend.
[0338] Results
[0339] PLX5622 improves metabolic function in middle-aged Magel2-null mice
[0340] Female Magel2-null mice, 9-10 months of age, were randomized to either PLX5622 diet PLX (+)) or normal chow diet (PLX (-)) for a total of 7 weeks. Body weight and food intake were monitored weekly. Magel2-null / PLX (+) mice showed considerable weight loss after 1 week while no significant effects of PLX5622 on body weight and weight change were observed over the 7-week experiment (FIG. 1A, IB). Prior to the initiation of PLX5622, an echoMRI was performed to assess body composition to allow for experimental group randomization. At 4 weeks post PLX5622 treatment, body composition was not different between the two groups (FIG. 1C, IE). However, Magel2-null / PLX (+) mice displayed a significant increase in lean mass and a trend of decrease in fat mass after 4-weeks PLX5622 treatment opposing to the changes in body composition of Magel2-null / PLX (-) control mice (FIG. ID, IF). Magel2-null / PLX (+) mice showed a small but significant decrease in food intake compared to Magel2-null / PLX (-) control mice (FIG. 1G). At 6 weeks post PLX5622 treatment, a glucose tolerance test was performed. Magel2-null / PLX (+) mice exhibited improved glucose tolerance compared to Magel2-null / PLX (-) control mice (FIG. 1H, P=0.048, two-way repeated measures ANOVA).
[0341] Mice were euthanized at 7 weeks post PLX5622 treatment after a 4h fast and tissues were harvested. The weights of the brown adipose tissue (BAT) and three white adipose tissue (WAT) depots — inguinal WAT (iWAT), gonadal WAT (gWAT), and retroperitoneal WAT (rWAT) were not different between the two groups (FIG. 2A). The relative iWAT weight calibrated to body weight was trending lower in Magel2-null / PLX (+) mice as compared to Magel2-null / PLX (-) control mice (P=0.078) (FIG 2B).
[0342] Serum samples were profiled to assess systemic changes following PLX treatment. Leptin is an adipokine that plays critical roles in regulating energy homeostasis. Loss of Magel2 results in leptin resistance in the hypothalamic POMC neurons contributing to the metabolic deficits in Magel2-null mice and hyperleptinemia. PLX5622 treatment had no effects on the serum levels of leptin, insulin, or glucose (FIG. 2C, 2D, 2E). The HOMA-IR (homeostatic model assessment for insulin resistance) index was not changed by PLX5622, suggesting lackDocket No. 103362-109W01
[0343] of effect on insulin sensitivity by PLX5622 (FIG. 2F). Moreover, PLX treatment did not alter the serum triglyceride levels (FIG. 2G). Interestingly, PLX treatment led to a small but significant reduction in the serum free fatty acids (FFA) levels (Fig. 2H).
[0344] PLX5622 partially depletes microglia and alters hypothalamic gene expression in middle aged Magel2-nu.ll mice
[0345] Previous work has shown that chronic PLX5622 treatment with the same regime depleted 75% of microglia from the hypothalamus in sex- and age-matched wildtype C57BL / 6J mice quantified by Ibal immunohistochemistry. In the present study, gene expression transcript was profiled in one hemisphere of hypothalamus by qRT-PCR (FIG. 3A, 3B) and protein levels were probed in the other hemisphere of hypothalamus by western blotting (Fig. 3C). Aifl (encoding allograft inflammatory factor 1, also known as Ibal) mRNA was 64% lower in Magel2-null / PLX (+) mice (FIG. 3A) and Ibal protein level was 86% lower compared to Magel2-null / PLX (-) control mice (FIG. 3C, 3D), indicating substantial depletion of microglia by PLX5622 while not eliminating Ibal+ cells within the hypothalamus. Additional microglial and inflammation associated genes were assessed. TMEM119 is a more specific marker for CNS resident microglia. PLX5622 treatment resulted in a 76% reduction in Tmemll9 gene expression.
[0346] Another marker specific for CNS microglia is fractalkine receptor CX3CR1. PLX5622 reduced Cx3crl (encoding CX3C motif chemokine receptor 1) gene expression by 63% together with a 76% reduction in microglia related gene Trem2 (encoding triggering receptor expressed on myeloid cells 2) (FIG. 3A). The collective reduction in microglial markers indicate robust but partial depletion of microglia by PLX5622. A previous study revealed a genotype-driven proinflammatory gene expression signature in Magel2-null mice as compared to WT mice including upregulation of Nfkbia (encoding nuclear factor-kappa-B-inhibitor alpha), CxcllO (encoding C-X-C motif chemokine ligand 10), Aim2 (encoding absent in melanoma 2), and Socs3 (encoding suppressor of cytokine signaling 3). Interestingly, PLX5622 had no effect on Nfkbia, CxcllO, Aim2, Socs3 or inflammation-related genes Illb (encoding interleukin 1 beta), Ikbkb (encoding inhibitor of nuclear factor kappa B kinase subunit beta), while downregulated Pycard, also known as ASC (Apoptosis-associated speck like protein containing a CARD) (FIG. 3A).
[0347] It was previously reported that hypothalamic BDNF gene therapy altered hypothalamic gene expression in Magel2-null mice. Accordingly, a set of genes involved in feeding and energy balance regulation were profiled. PLX5622 treatment resulted in upregulation of CrhDocket No. 103362-109W01
[0348] (encoding corticotrophin-releasing hormone) and Mc4r (encoding melanocortin 4 receptor) while had no significant effect on the expression of Bdnf and its receptors-TrkB-FL (encoding tropomyosin receptor kinase B full length) and TrkB-Tl (encoding truncated form of tropomyosin receptor kinase B), Npy (encoding neuropeptide Y), Pome (encoding proopiomelanocortin), Obrb (encoding leptin receptor long-form), Insr (encoding insulin receptor) or Glplr (encoding glucagon-like peptide-1 receptor) (FIG. 3B).
[0349] PLX5622 modulates adipose tissue gene expression in middle-aged Magel2-null mice Previous work showed that PLX5622 modulated adipose tissue macrophage in female middle-aged WT mice. As such, gene expression was profiled in the BAT and iWAT by qRT PCR. PLX5622 treatment resulted in a significant downregulation of the macrophage marker Emrl (also known as F4 / 80) in both iWAT and BAT (FIG. 4A, 4C) while had no effect on the expression of additional macrophage markers or inflammation related genes including Ccl2 (encoding chemokine ligand 2), Cdllc (encoding integrin alpha X), CxcllO, Il lb, Tnfa (encoding tumor necrosis factor-a), Pycard, and Cd36 (encoding platelet glycoprotein 4, also known CD36 blood group) (FIG. 4A, 4C). Ccl2 (encoding chemokine ligand 2) was not altered by PLX5622 treatment in the BAT but was upregulated in the iWAT (Fig. 4A, 4C). Ccl2 is a monocyte and macrophage chemokine whose upregulation in iWAT might reflect a compensatory response to PLX-induced macrophage depletion in adipose tissue.
[0350] Adipose functional genes were profiled. PLX5622-induced upregulation of Hsl (encoding hormone-sensitive lipase, the crucial enzyme in lipolysis) and Pparg (encoding peroxisome proliferator-activated receptor gamma) was observed in the iWAT (FIG. 4B) but not in the BAT (FIG. 4D). Instead, PLX5622 led to a significant upregulation of Ppargcla (encoding peroxisome proliferator-activated receptor gamma coactivator 1 -alpha), a transcriptional coactivator regulating genes involved in energy metabolism, in the BAT (FIG.
[0351] 4D). However, the expression of Ucpl (encoding uncoupling protein 1), the key thermogenic protein, was trending higher in the Magel2-null / PLX (+) mice but did not reach significance (FIG. 4D). No PLX5622 -induced changes were observed in Adrb3 (encoding adrenoceptor 3), Lep (encoding leptin), Adipoq (encoding adiponectin), Cfd (encoding complement factor D, or adipsin), Srebplc (encoding sterol regulatory element-binding protein 1, isoform c) in either iWAT (FIG. 4B) or BAT (FIG. 4D). The expression of Srebplc (encoding sterol regulatory element-binding protein 1, isoform c) and Acaca (encoding acetyl-CoA carboxylase alpha, ACC1) was trending higher in the iWAT of but not Magel2-null / PLX (+) mice but not reach significance (Fig. 4B).Docket No. 103362-109W01
[0352] PLX5622 downregulates inflammatory and lipogenic gene expression in the liver of middle aged Magel2-nu.ll mice
[0353] In contrast to the mild changes in adipose tissue gene expression, PLX5622 led to a collective downregulation of macrophage related and / or immune response related genes, e.g. Emrl reduced by 76%, Trem2 by 76%, Illb by 77%, and Tnfa by 65% (Fig. 5A). Cdllc, CxcllO, Nfkbia, Pycard, and 1133 (encoding interleukin-33) were all significantly downregulated by PLX5622 ranging from 23% to 54% (FIG. 5A).
[0354] As aging is associated with impaired suppression of hepatic glucose production and hepatosteatosis in WT mice, gene expression of enzymes and signaling molecules critical for both processes in the middle-aged Magel2-null mice were examined after chronic PLX5622 treatment. qRT-PCR revealed significant downregulation of Chrebpb (encoding carbohydrateresponsive element-binding protein isoform b), the transcription factor regulates glucose and lipid metabolism, Fasn (encoding fatty acid synthase), Gpat (encoding glycerol-3-phosphate acyltransferase), the rate-limiting enzyme in the de novo glycerolipid synthesis, and Scd2 (encoding stearoyl-coenzyme A desaturase 2), crucial in the synthesis of monounsaturated fatty acids in the livers from Magel2-null / PLX (+) mice (FIG. 5B). Interestingly, Gpdl (encoding glycerol-3-phosphate dehydrogenase 1), involved in NADH oxidation, was significantly upregulated by PLX5622 (FIG. 5B). Moreover, the expression of the major gluconeogenic enzyme, glucose-6-phosphatase (encoded by G6pc), was downregulated by PLX5622 together with the Prkce (encoding Protein kinase Ce) (FIG. 5B). PKCe is thought to play a role in lipid-induced hepatic insulin resistance and the resulting impaired insulin-induced suppression of hepatic gluconeogenesis.
[0355] Western blotting confirmed the reduction in the protein levels of FASN by 35% and PKCe by 44% in PLX5622-treated Magel2-null mice (FIG. 6A, 6B). The protein level of SREBP1, the major transcription factor that regulates de novo lipogenesis enzymes, was significantly reduced by 24% in Magel2-null / PLX (+) mice (FIG. 6A, 6B), consistent with reduced steatosis. No significant alterations in ChREBPl protein level and phosphorylation of AKT were observed (FIG. 6A, 6B). Moreover, liver content of triglyceride was not altered by chronic PLX5622 treatment (FIG. 6C).
[0356] PLX5622 exerts lesser effects in young Magel2-null miceDocket No. 103362-109W01
[0357] To determine whether PLX5622’s effects were age-dependent, 3-months old female Magel2-null mice were subject to PLX5622 treatment mirroring the middle-aged cohort. Sex-and age- matched WT mice were given PLX (-) diet as a normal control. Body weight or weight change (percentage from baseline) were not significantly different between the groups (FIG.
[0358] 7 A, 7B). Body composition was measured prior to PLX5622 treatment and after 4-weeks and 10-weeks of PLX5622 treatment (FIG. 7C, 7D). Neither the fat mass change nor the lean mass change significantly differed between groups (FIG. 7D, 7F). Interestingly, increased food intake was observed in Magel2-null / PLX (-) mice as compared to WT / PLX (-) mice, which was reversed by PLX5622 treatment (FIG. 7G). However, no genotype- or PLX- effect on glucose tolerance was observed after 6-weeks PLX5622 treatment (FIG. 7H). Mice were euthanized after 11 -weeks PLX5622 treatment. Magel2-null / PLX (-) mice exhibited increased WAT weights as compared to WT counterparts (FIG. 8A, 8B). PLX5622 treatment attenuated this genotypic effect to various degrees dependent on the WAT depots (FIG. 8A, 8B). Of note, the spleen mass was significantly lower in the Magel2-null / PLX (+) mice than the other two groups not treated with PLX5622 (FIG. 8 A). Genotype-associated hyperleptinemia was not affected by PLX5622 treatment (FIG. 8C). No genotype- or PLX- effects on serum insulin, serum glucose, or HOMA-IR were observed. (FIG. 8D, 8E, 8F). Genotype-associated elevation in serum FFA was attenuated by PLX treatment but not reach significance (Fig. 8G).
[0359] Similarly to the middle-aged cohort, PLX5622 resulted in a robust downregulation of microglia genes and inflammatory genes in the hypothalamus (FIG. 9A). PLX5622 decreased Ibal protein level in the hypothalamus by 76% in the young cohort (FIG. 9C, 9D), identical to the reduction in the middle-aged cohort (FIG. 3D). Of note, genotypic alterations in the microglial or inflammatory genes were not observed (FIG. 9A). Compared to WT / PLX (-) mice, the TrkB-FL and Obrb mRNA levels were higher in Magel2-null mice with or without PLX5622 treatment (FIG. 9B).
[0360] Liver phenotypic changes induced by PLX5622 were less notable in the young cohort (FIG. 10) than those observed in the middle-aged cohort (FIG. 5, FIG. 6). No genotype-associated changes in macrophage markers and genes involved in immune response were observed (FIG. 10A). In contrast, PLX5622 resulted in robust downregulation of CxcllO, Emrl, Il lb, Pycard, and Trem2, a similar pattern observed in middle-aged cohort (FIG. 10A). Genes involved in lipogenesis and gluconeogenesis were not differentially expressed regardless of genotype or PLX5622 treatment (FIG. 10B). Western blotting showed a significant reduction in SREBP1 protein level because of genotype (FIG. 10C, 10D). The PKCeDocket No. 103362-109W01
[0361] level in the Magel2-null / PLX (-) mice was trending lower compared to WT / PLX (-) mice and PLX5622 treatment furtherly lowered the PKCe level (FIG. 10C, 10D).
[0362] Discussion
[0363] Standard of care for PWS remains growth hormone therapy and strict supervision of daily food intake. Limitations of growth hormone therapy include requiring patient compliance, lacking efficacy data in older adults, and exclusion of patients with common comorbidities such as severe obesity, uncontrolled diabetes, or active psychosis. Strict supervision of daily food intake and management of emotional reactivity of individuals with PWS results in high levels of caregiver burden, which might exceed that of caregivers for patients with Alzheimer’s and traumatic brain injury. Recent pharmacological developments have been mostly targeting the hypothalamic leptin-POMC pathway through MC4R agonists — Melanotan II (MT-II) and setmelanotide. Additional categories of therapeutics have been tested in animal models and clinical trials at various stages whereas none has been approved by FDA to treat compulsive eating and emotional reactivity, underscoring the urgent need for new therapeutic strategies.
[0364] Previous work has demonstrated that hypothalamic injection of an autoregulatory AAV-BDNF vector efficiently mitigates deficits in the leptin-POMC signaling pathway to alleviate obesity, impaired glucose metabolism, fatty liver, and other metabolic syndrome in genetic, diet-induced, and aging-related models of obesity. The hypothalamic AAV-BDNF gene therapy has shown high level of efficacy and safety in the Magel2-null model of PWS. However, translating hypothalamic BDNF gene therapy to the clinic remains challenging. Thus, alternative approaches to stimulating hypothalamic BDNF should be explored.
[0365] For example, previous research has demonstrated that environmental enrichment (EE) — a housing condition providing complex physical, social, and cognitive stimulations — exerts a wide range of health benefits across the lifespan of mice. Hypothalamic BDNF has been identified as a key brain mediator coordinating the EE-induced diverse effects on body composition, energy balance, immunity, cancer, behavior, and healthy aging. It was recently reported that EE initiated after the occurrence of metabolic dysfunction could normalize metabolic function in the male Magel2-null mice, mimicking the metabolic effects of hypothalamic AAV-BDNF gene therapy but not the behavioral effects. Unexpectedly, this study suggests hypothalamic BDNF might not be a critical mediator of EE effects in the Magel2-null mice as opposed to wildtype mice. These new data suggest biobehavioral interventions could be effective in treating PWS-related metabolic syndromes and thereby warranting furtherDocket No. 103362-109W01
[0366] investigation. However, behavioral and lifestyle interventions are difficult to implement in the long-term in humans. Hence, small molecules remain the focus of therapeutic development.
[0367] Here, a new category of therapeutics were tested — a CSF1R inhibitor in a PWS model. Chronic CSF1R inhibition by PLX5622 improved metabolic outcomes in middle-aged female Magel2-null mice but not to the same degree in the young adult mice although depletion of microglia from the hypothalamus did not differ between the two age cohorts. The agedependent effects of PLX5622 were observed in middle-aged WT mice but not in young mice in a previous study, supporting the hypothesis that aged microglia (manifesting age-related morphological, functional, metabolic, and inflammatory alterations) contribute to age related metabolic decline. Of note, the current study mirrored the study setting of a previous study in WT mice including strain, sex, age, and PLX5622 regime. PLX5622 treatment resulted in significantly reduced food intake and improved glucose tolerance in the Magel2-null mice (Fig.
[0368] 1G, 1H) but not in the WT mice at the same age, indicating therapeutic potential.
[0369] Recent research has demonstrated that PLX5622 does not specifically target microglia but also affects hematopoiesis and macrophages in multiple peripheral tissues (adipose tissue, colon, lung). Robust downregulation of macrophage marker genes and / or genes involved in immune response were observed in the liver and in the adipose tissue to a lesser degree, in support of the notion that PLX5622 exerts metabolic effects through peripheral immune modulation. However, the current study was unable to discern the central versus peripheral immune effects of CSF1R inhibition by PLX5622. A monoclonal CSF1R antibody was found to have no effect on microglia but deplete macrophages across multiple peripheral tissues in mice with an intact blood-brain barrier. Future studies using this anti-CSFIR antibody or clodronate liposomes to deplete peripheral macrophages may help to determine whether PLX5622 modulates metabolic functions in the Magel2-null mice through brain microglia, peripheral macrophages, or both.
[0370] It was recently reported that PLX5622 depleted macrophages while increasing eosinophils and group 2 innate lymphoid cells in multiple tissues including adipose tissue, colon, lung, and peritoneum in lean WT mice. CSF1R inhibition by PLX5622 improved hepatic insulin sensitivity but concomitantly impaired insulin secretion through depletion of IL-lb+ islet macrophages. Impaired whole-body glucose tolerance was found after 2-months PLX5622 treatment in male WT mice. The studies applied the same PLX5622 regime (1200 ppm in AIN76 diet) but no adverse effect on glucose tolerance was observed in female WT mice regardless of age. Moreover, PLX5622 resulted in improved glucose tolerance in middle-aged Magel2-null mice. There are differences between Bosch study and the present studies in mouseDocket No. 103362-109W01
[0371] strain, sex, age when PLX5622 treatment initiated, and glucose tolerance test protocol (time of fast, dose of glucose, etc.), which could explain the inconsistency.
[0372] One new finding of the present study is the liver effects of PLX5622 in the Magel2-null mice. It is reported that PLX5622 treatment led to lesser effects on liver macrophages compared to other tissue resident macrophages in colon, adipose tissue, and lung depending on CSF1R expression levels. PLX5622 did not deplete liver macrophages in male WT mice and reduced liver macrophage frequency in female WT mice after 4-weeks PLX5622 treatment but not at 3-weeks exposure. These data show a PLX5622-induced hepatic gene expression signature characterized as robust downregulation of macrophage markers and inflammatory genes, indicating depletion of liver macrophages in the Magel2-null mice. Notably, this downregulation of genes involved in immune response was independent of age, raising the question whether liver resident macrophages in the Magel2-null mice exhibit increased sensitivity to PLX5622 through higher level of CSF1R expression.
[0373] The present study reveals suppression of genes involved in hepatic glucose production (HGP) and de novo lipogenesis by PLX5622 depending on age. It is possible that liver phenotypes of Magel2 deficiency develop at older age and therefore allowing the observation of PLX5622 modulation of liver. HGP plays a crucial role in systemic glucose homeostasis and is regulated through diverse mechanisms. Impaired suppression of HGP is associated with nonalcoholic fatty liver disease. The activation of PKCe is thought to serve as a mechanism linking hepatosteatosis, hepatic insulin resistance, and impaired glycemic control in metabolic disease models. In the middle-aged Magel2-null mice, PLX5622 reduced the mRNA and protein levels of PKCe concomitant with decreased level of SREBP1, FASN, and G6PC (FIG. 6). However, liver triglyceride contents were not altered. In addition, PLX5622 treatment improved glucose tolerance in the middle-aged mice but had no effect on HOMA-IR (FIG. 2). Bosch et al. found that glucose uptake to adipose tissue was not altered by PLX5622 in WT mice while glucose uptake to skeletal muscle was trending up associated with reduction in systemic triglyceride and alanine aminotransferase and aspartate aminotransferase after 4-5 months of PLX5622 treatment, longer than the 7-weeks duration in the present study.
[0374] One unexpected finding of the current study is that hepatic SREBP1 was significantly lower in the Magel2-null / PLX (-) mice and the PKCe was also trending lower as compared to WT / PLX (-) mice (Fig. 10C, 10D) when increased adiposity and hyperleptinemia occurred (Fig. 8) in the young cohort. Leptin suppresses HGP and can exert a dual action on nonalcoholic fatty liver disease models — antisteatotic or proinflammatory / profibrogenic, in a contextDocket No. 103362-109W01
[0375] dependent manner. Loss of Magel2 causes leptin resistance in the hypothalamic POMC neurons that results in the metabolic deficits in Magel2-null mice and extreme hyperleptinemia.
[0376] Scarce data is available regarding plasma FFA levels in individuals with PWS and none is reported in the Magel2-null mice. As described herein, PLX5622 treatment led to a significant reduction in the serum FFA levels in middle-aged Magel2-null mice (FIG. 2H) and an attenuation of genotype-driven effect on FFA in the young cohort (FIG. 8G). Interestingly, lipolytic gene Hsl was upregulated in the iWAT while lipogenic genes Srebplc and Acaca were trending higher (FIG. 4B). While not wishing to be bound to any one theory, PLX treatment can affect the balance between lipolysis and lipogenesis within WAT. In addition, WAT mass was trending lower in PLX treated mice (FIG. 2B). While not wishing to be bound by any one theory, lower WAT mass as a result of PLX treatment can contribute to the decrease in serum FFA. As circulating FFA levels are elevated in obesity and obesity related comorbidities such as metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and cardiovascular disease, reducing circulating FFA concentration is thought to improve health. The PLX-induced reduction of FFA has implications in metabolic diseases.
[0377] It was previously demonstrated that Magel2-null mice receiving a control AAV-YFP vector displayed a hypothalamic neuroinflammatory gene expression signature compared to WT mice receiving AAV-YFP. AAV-BDNF gene therapy reversed this hypothalamic neuroinflammatory signature in both male and female Magel2-null mice. Herein, this genotype driven neuroinflammatory gene expression signature was not observed in mice that did not receive stereotaxic surgery (FIG. 9A), consistent with the data obtained in the EE study. Together, these findings suggest that stereotaxic injection to the hypothalamus may contribute to the robust stimulation of microglial and proinflammatory markers in the Magel2-null mice receiving the control AAV-YFP, manifestation of increased glial scar in response to surgery as compared to WT mice receiving the same control AAV vector. BDNF overexpression alleviated the genotype-driven heightened gliosis. However, the current study does not rule out the potential role of microglia in PWS pathogenesis due to lack of investigation of microglia morphology and functional state.
[0378] While not wishing to be bound by any one theory, CSF1R inhibition by PLX5622 leads to metabolic improvement in the PWS model female Magel2-null mice in an age-dependent manner. PLX5622 treatment results in depletion of microglia, downregulation of macrophage markers and genes involved in immune response in the liver, and suppression of genes critical for HGP and lipogenesis in the middle-aged mice. These data provide evidence in support ofDocket No. 103362-109W01
[0379] developing immune-modulatory therapeutics for the treatment of PWS, a genetic disease in urgent need of new therapeutic strategies.
[0380] Example 2. CSF1R inhibitor PLX5622 improves metabolic function in middle-aged female Magel2-nu\\ model of Prader-Willi syndrome
[0381] Prader-Willi syndrome (PWS) is a rare genetic disease characterized by developmental delays, intellectual impairment, excessive hunger, obesity and associated metabolic dysfunction, and various behavioral abnormalities. Standard care of PWS is limited to growth hormone therapy and strict supervision of food intake, highlighting the urgent need for new therapeutic strategies. Previous work revealed a proinflammatory trans criptomic profde in the hypothalamus of Magel2-mA\ mouse model of PWS, recapitulating the hypothalamic inflammation and activation of microglia in individuals with PWS. Hypothalamic microinflammation is a known driver of metabolic syndrome in various obesity models while its role in PWS remains poorly understood. Here, it was evaluated how microglia depletion affected metabolic functions mMagel2-nu\\ mouse model of PWS.
[0382] CSF1R inhibitor PLX5622 was used to pharmacologically deplete microglia. Two age cohorts of female Magel2-mA\ mice and wildtype mice: middle-aged (9-10-months), young adult (3-5-months), were randomized to receive PLX5622 formulated diet for 7 weeks. Weight, food intake, glucose tolerance, serum biomarkers, hypothalamic and hepatic gene expression were determined.
[0383] In the middle-aged cohort, PLX5622 treatment resulted in significant amelioration of genotypic increase of food intake and significant improvement in glucose metabolism in Magel2-mA\ mice while exerted no effect on glucose tolerance in wildtype counterparts. These metabolic improvements were associated with antiinflammation gene signature in the liver and reduced hepatic signaling pathways involved in gluconeogenesis and de novo lipogenesis in Magel2-mA\ mice. However, PLX5622 exerted lesser metabolic effects in young adult Magel2-null mice.
[0384] These results suggest PLX5622 could be effective in the treatment of PWS-related metabolic abnormalities in an age-dependent manner warranting further investigation.
[0385] Prader-Willi syndrome (PWS) is a rare genetic disease, occurring in approximately 1 in 15,000 individuals, and is caused by the loss of function of paternally inherited copy of chromosome 15qll-ql3. PWS patients display developmental delays, cognitive impairment,Docket No. 103362-109W01
[0386] behavioral and neuropsychiatric abnormalities, endocrine dysfunction, hypothalamic hypogonadism, and constant sense of hunger (hyperphagia) that often leads to obesity and many obesity-related complications.
[0387] Bochukova and colleagues recently described a genetic signature of PWS by performing RNA sequencing on post-mortem hypothalamic tissue from PWS patients and age-matched controls. The group reports the transcriptomic profile of PWS hypothalamus characterized as a downregulation of genes involved in neuronal function and an upregulation of microglial genes and inflammatory markers. The authors identified brain-derived neurotrophic factor (BDNF) to be a potential upstream regulator of the observed PWS-associated genetic signature. PWS individuals exhibit a reduction in BDNF and its receptor, which is thought to underlie PWS -influenced neuronal loss, altered neuroplasticity, and neuroinflammation.
[0388] Despite the valuable human data implicating microglia in PWS pathogenesis, research exploring the neuroinflammation signature in PWS-relevant animal models remains scarce. Hypothalamic “microinflammation” has been recognized as a driver of metabolic syndrome. Microglial cells are the resident immune cells of the central nervous system. Upon activation, microglial cells can generate proinfl ammatory molecules, enable phagocytosis, and present antigens. Microglial cells also orchestrate the hypothalamic inflammatory response to dietary excess and mediate obesity susceptibility. Although the current literature is limited, it is plausible that microglial cells are intertwined with PWS-relevant metabolic outcomes.
[0389] MAGEL2 (MAGE Family Member L2) is one of the five protein-coding genes in the PWS-critical domain on chromosome 15qll-ql3 and its loss contributes to disturbed energy homeostasis in PWS. Magel2-mA\ mice recapitulate some aspects of PWS pathophysiology including disturbance in the hypothalamic leptin-proopiomelanocortin (POMC) pathway and feeding circuitry, increased adiposity, impaired glucose metabolism, and alterations in neuroendocrine responses. Previous work has demonstrated that hypothalamic adeno-associated virus (AAV)-mediated BDNF gene therapy normalized metabolic and behavioral abnormalities in the Magel2-mA\ mouse model of PWS. Moreover, mRNA-sequencing data demonstrate that Magel2-mA\ mice mirror the neuroinflammatory gene signature observed in the hypothalamus of patients with PWS including the upregulation of microglial genes. Furthermore, hypothalamic AAV-BDNF gene therapy reversed the hypothalamic inflammatory gene signature in the Magel2-mA\ mice concomitant with systemic metabolic improvements. As such, it was hypothesized that hypothalamic microglia may play a role in the metabolic dysfunction in Magel2 deficiency and thereby a potential therapeutic target. In this study,Docket No. 103362-109W01
[0390] PLX5622, a highly potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), was used to pharmacologically deplete microglia and assess whether microglia depletion could ameliorate the metabolic disturbance mMagel2-mx\\ mice.
[0391] Materials and Methods
[0392] Mice
[0393] Magel2-mA\ mice harbor a maternally inherited imprinted / silenced wild type allele and a paternally inherited Magel2-lacZ knock-in allele that abolishes endogenous Magel2 gene function. Male mice containing the Magel2-lcicZ allele (Jackson Labs #009062, RRID:IMSR__.JAX:009062) on C57BL / 6J strain were bred with female C57BL / 6J mice to produce both wild type mice and Afoge / 2-null littermates. Mice were genotyped from ear notch biopsies. Identification of mutant offspring was performed by polymerase chain reaction genotyping with Magel2 and LacZ oligonucleotide primers (common forward, 5'-ATGGCTCCATCAGGAGAAC (SEQ ID NO: 103); Magel2 reverse, 5'-GATGGAAAGACCCTTGAGGT (SEQ ID NO: 104); and LacZ reverse, RW4237, 5'-GGGATAGGTCACGTTGGTGT (SEQ ID NO: 105)). Genotype was further confirmed by qRT-PCR detecting Magel2 transcript in the hypothalamus. Mice were housed within temperature (22-23°C) and humidity (30-70%) controlled rooms under a 12: 12 light: dark cycle. All mice had ad libitum access to food and water. All animal experiments were in accordance with the regulations of The Ohio State University’s Institutional Animal Care and Use Committee (IACUC), protocol approval 2012A00000060-R3.
[0394] PLX5622 treatment
[0395] CSF1R inhibitor PLX5622 was provided by Plexxikon, Inc. (Berkley, CA) and formulated at 1200 ppm into rodent diet AIN-76A (12% fat, caloric density 3.86kcal / g) by Research Diets, Inc. (New Brunswick, NJ). For middle aged cohort, female Magel2-mA\ mice, 9-10 months of age, were randomized to receive either the PLX5622 formulated diet or a normal chow diet (AIN-76A) for 7 weeks. Sex- and age-matched wildtype mice were subject to the same diets as Magel2-mA\ mice. For young adult cohort, female Magel2-mA\ mice and wildtype mice, 3-5 months of age, were randomized to receive either PLX5622 formulated diet or AIN-76A diet for 7 weeks.
[0396] Body weight and food intake measurementDocket No. 103362-109W01
[0397] Body weight was monitored weekly throughout the experiments. Food intake was recorded at the cage level on a weekly basis throughout the experiments. Average food intake was calculated on a per-mouse per-day basis excluding the data collected in weeks during which invasive procedures occurred (e.g., overnight fast for glucose tolerance test).
[0398] Glucose tolerance test
[0399] At 6 weeks on PLX treatment, mice were injected intraperitoneally with glucose solution (1.0 g glucose per kg body weight) after a 16 h overnight fast. Blood was obtained from the tail at 0, 15, 30, 60, 90, and 120 min after glucose injection. Blood glucose concentrations were measured with a portable glucose meter using default manufacturer settings (Bayer Contour Next). Following blood collection, styptic powder was used to stop bleeding.
[0400] Tissue collection
[0401] Mice were anesthetized with 2.5% isoflurane (1.0 L / min) following a 4h fast and then decapitated to collect trunk blood. Hypothalamus was dissected under a dissection microscope, with the left and right side being collected separately to allow for RNA and protein isolation from each mouse. Fat pads including intrascapular brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), and retroperitoneal white adipose tissue (rWAT), liver, and spleen were collected and weighed. Tissues to be used for mRNA and protein analyses were flash frozen on dry ice and stored at -80°C until further analysis.
[0402] Serum harvest and analysis
[0403] Trunk blood was collected, clotted on ice, and centrifuged at 10,000 rpm for 10 min at 4°C. The serum component was harvested and stored at -20°C until further analysis. ELISAs were performed to assay serum leptin (R and D Systems Cat# DY498, RRID: AB 3668792) and serum insulin (Alpco Diagnostics Cat# 80-INSMSU-E01, RRID: AB_2792981). Caymen Chemical colorimetric assay kit was used to assay glucose (#10009582). HOMA-IR (homeostatic model assessment for insulin resistance) index was calculated as [fasting serum glucose (mmol / L) x fasting serum insulin (pmol / L) / 22.5] as described elsewhere.
[0404] Hepatic triglyceride quantificationDocket No. 103362-109W01
[0405] Lipids were extracted from liver tissue by chloroform / methanol (2:1 v / v), followed by rinses in 50 mM NaCl and CaCh (0.36M) / Methanol (1:1 v / v). Hepatic triglyceride was quantified with a Caymen Chemical triglyceride assay kit (#10010303).
[0406] Quantitative RT-PCR
[0407] Following tissue sonication, RNA was isolated using the QIAGEN RNeasy Mini kit (#74804). cDNA was reverse transcribed using Taqman Reverse Transcription Reagents (Applied Biosystems #N8080234). qRT-PCR was conducted on the StepOnePlus Real-Time PCR System using Power SYBR Green (Applied Biosystems #A25742) PCR Master Mix. Data were calibrated to endogenous controls — Hprtl for hypothalamus, Ppia for liver. The relative gene expression was quantified using the 2-AACTmethod.
[0408] Western blotting
[0409] Hypothalamus and liver tissues were homogenized in ice-cold RIPA buffer (Pierce #89901) containing lx PhosSTOP (Roche #4906845001) and protease inhibitor cocktail III (Calbiochem #539134). Tissues lysates were spun at 13,000 rpm for 15 min at 4 °C and the supernatant was collected. The protein concentration was determined with a BC A protein assay kit (Pierce). 30 pg protein from each sample was loaded and separated by gradient gel (4-20%, Mini-PROTEAN TGX, Bio-Rad), then transferred to a nitrocellulose membrane (BIO-RAD). Blots were incubated overnight at 4 °C with the following primary antibodies: Vinculin (Cell Signaling Technology Cat# 13901, RRID:AB_2728768, 1:1000), Ibal (FUJIFILM Wako Pure Chemical Corporation Cat# 016-20001, RRID:AB_839506, 1:500), Fatty acid synthase (Cell Signaling Technology Cat# 3180, RRID:AB_2100796 , 1:1000), SREBP1 (Novus Cat# NB100-2215, RRID :AB_10002406 , 1:200), PKCe (Cell Signaling Technology Cat# 2683, RRID:AB_2171906 , 1:1000), p-Actin (Cell Signaling Technology Cat# 4970, RRID:AB_2223172 ,1:1000). Blots were rinsed and incubated with HRP-conjugated secondary antibodies (Bio-Rad, 1:3000). Chemiluminescence signal was detected and visualized by LI-COR Odyssey Fc imaging system (LI-COR Biotechnology, Lincoln, NE). Quantification analysis was carried out with Image Studio software version 5.2 (LI-COR Biotechnology).Docket No. 103362-109W01
[0410] Quantification and statistical analysis
[0411] Statistical analyses were performed using GraphPad Prism 10 software (GraphPad, San Diego, CA, USA). Unpaired t test with Welch’s correction was utilized for comparisons between two groups. Two-way ANOVAs (genotype x PLX) with Tukey’s post hoc test were used for comparisons between four groups. If interaction was significant, uncorrected Fisher’s LSD test was used for comparison between same-genotype PLX (+) vs PLX (-). Normality was tested using the Shapiro-Wilk method. Significance was defined as P < 0.05. Data are reported as means ± SEM. Sample sizes (n) can be found in each figure’s respective legend.
[0412] Results
[0413] PLX5622 improves metabolic function in middle-aged Magel2-null mice
[0414] Female Magel2-mA\ mice and wildtype (WT) mice, 9-10 months of age, were randomized to either PLX5622 diet (PLX (+)) or normal chow diet (PLX (-)) for a total of 7 weeks. Body weight and food intake were monitored weekly. Magel2-mA\ mice showed significantly higher body weight compared to WT mice throughout the experiment (FIG. 11 A, 11B). No significant effects of PLX5622 on body weight were observed over the 7-week experiment (FIG. 11 A, 11B). PLX5622 treatment led to considerable weight loss after 1 week in both Magel2-mA\ and WT mice (FIG. 11C). Factor analysis revealed a significant effect of PLX on weight change over the 7-week experiment (FIG. 1 ID), although multiple comparisons between same-genotype were not significant (FIG. 11D). Total weight changes were not significantly different among the four groups (FIG. HE). A genotype-driven increase in food intake was observed in Magel2-mA\ mice as compared to WT mice (FIG. HF). PLX5622 treatment exerted significant effect on food intake and ameliorated genotype-driven increase in food intake (FIG. 1 IF).
[0415] At 6 weeks post PLX5622 treatment, a glucose tolerance test was performed. Magel2-null mice exhibited worsened glucose tolerance compared to WT mice (FIG. 12A, 12B). Two-way ANOVA revealed significant interaction between genotype and PLX5622 treatment (FIG.
[0416] 12B). PLX5622 treatment significantly improved glucose tolerance in ATo c / 2-null mice while had no effect in WT mice (FIG. 12B).
[0417] Mice were euthanized at 7 weeks post PLX5622 treatment after a 4h fast and tissues were harvested. The weights of the brown adipose tissue (BAT) and three white adipose tissue (WAT) depots — inguinal WAT (iWAT), gonadal WAT (gWAT), and retroperitoneal WAT (rWAT) were significantly higher in Magel2-mA\ mice as compared to WT mice (FIG. 13 A,Docket No. 103362-109W01
[0418] 13B, 13C, 13D). PLX5622 treatment exerted significant effect on adipose tissue weight only in iWAT (FIG. 13B). The relative iWAT weight calibrated to body weight was significantly lower in ATogc72-null / PLX (+) mice as compared to ATogc72-null / PLX (-) mice (FIG. 20B). An increase in liver weight was observed in Magel2-mA\ mice as compared to WT counterparts while PLX5622 treatment showed no effect (FIG. 13E). In contrast, PLX5622 treatment resulted in a significant reduction in spleen weight by Two-Way ANOVA (FIG. 13F).
[0419] Serum samples were profiled to assess systemic changes following PLX5622 treatment. Significant genotype-effects on serum glucose levels (FIG. 14 A), insulin levels (FIG. 14B), and HOMA-IR (homeostatic model assessment for insulin resistance) index (FIG. 14C) were observed, while PLX5622 treatment showed no significant effects (FIG. 14A, 14B, 14C). Leptin is an adipokine that plays critical roles in regulating energy homeostasis. Loss <AMagel2 results in leptin resistance in the hypothalamic POMC neurons contributing to the metabolic deficits in Magel2-mA\ mice and hyperleptinemia. Genotype-driven hyperleptinemia was observed while PLX5622 treatment had no effects on the serum leptin levels (FIG. 14D).
[0420] PLX5622 partially depletes microglia and alters hypothalamic gene expression in middle-aged Magel2-nu.ll mice
[0421] Previous work has shown that chronic PLX5622 treatment with the same regime depleted 75% of microglia from the hypothalamus in sex- and age-matched wildtype C57BL / 6J mice quantified by Ibal immunohistochemistry. In the present study, gene expression transcript was profiled in one hemisphere of hypothalamus by qRT-PCR (FIG. 15) and protein levels were probed in the other hemisphere of hypothalamus by western blotting (FIG. 16A). Aifl (encoding allograft inflammatory factor 1, also known as Ibal) mRNA was 63% lower in Afage / 2-null / PLX (+) mice (FIG. 15) and Ibal protein level was 86% lower compared to Afage / 2-null / PLX (-) mice (FIG. 16B), indicating substantial depletion of microglia by PLX5622 while not eliminating Ibal+ cells within the hypothalamus. Additional microglial-associated genes were assessed. TMEM119 is a more specific marker for CNS resident microglia. PLX5622 treatment resulted in a 74% reduction in Tmemll9 gene expression in Magel2-nu\\ mice (FIG. 15). Another marker specific for CNS microglia is fractalkine receptor CX3CR1. PLX5622 reduced Cx3crl (encoding CX3C motif chemokine receptor 1) gene expression by 70% in Magel2-nu\\ mice (FIG. 15). No genotypic effects on microglial-associated genes were observed. PLX5622 treatment led to approximately 70% reduction in gene expression o Aifl, Cx3crl, and Tmemll9 in WT mice (FIG. 15). The collective reductionDocket No. 103362-109W01
[0422] in microglial markers indicate robust but partial depletion of microglia by PLX5622 regardless of genotypes.
[0423] It was previously reported that hypothalamic BDNF gene therapy altered hypothalamic gene expression in Magel2-mA\ mice. Accordingly, a set of genes involved in feeding and energy balance regulation were profded. A genotype-driven downregulation of Bdnf was observed while PLX5622 treatment had no significant effect (FIG. 15). In contrast, PLX5622 treatment resulted in a significant upregulation of BDNF receptor TrkB-FL (encoding tropomyosin receptor kinase B full length) (FIG. 15). Neither genotype nor PLX5622 effects on Mc4r (encoding melanocortin 4 receptor) or Obrb (encoding leptin receptor long-form) were observed (FIG. 15).
[0424] PLX5622 alters hepatic gene expression in middle-aged Magel2-nu.ll mice
[0425] Liver phenotype and molecular changes in Magel2-mA\ mice were not profiled in previous studies. As such, hepatic gene expression was profiled to determine genotype and PLX5622 treatment effects. PLX5622 treatment led to a collective downregulation of macrophage related and / or immune response related genes, including Aifl, Cx3crl, Emrl (also known as F4 / 80), Cdllc (encoding integrin alpha X), and Tnfa (encoding tumor necrosis factor alpha) regardless of genotype (FIG. 17). Unexpectedly, genotypic downregulation of Cx3crl and Tnfa were observed (FIG. 17).
[0426] As Magel2-mA\ mice exhibited increased liver weight as compared to WT mice (FIG.
[0427] 13E), gene expression of enzymes and signaling molecules critical for lipid metabolism were profiled. qRT-PCR revealed genotype-dependent effects of PLX5622 (FIG. 18). PLX5622 treatment resulted in significant downregulation of Fasn (encoding fatty acid synthase) in Magel2-mA\ mice while upregulation in WT mice (FIG. 18). Significant interaction between genotype and PLX5622 treatment was also found in Scdl (encoding stearoyl-coenzyme A desaturase 1) expression and PLX5622 led to opposing effects dependent on genotype. Similar trend was observed in the expression of Gpat (encoding glycerol-3-phsphate acyltransferase), the rate-limiting enzyme in the de novo glycerolipid synthesis. Scd2 (encoding stearoylcoenzyme A desaturase 2), enzyme crucial in the synthesis of monounsaturated fatty acids, was significantly upregulated as a result of loss of Magel2. This genotype-driven upregulation was significantly reversed by PLX5622 treatment (FIG. 18). The expression of Srebplc (encoding sterol regulatory element-binding protein 1 , isoform c), maj or transcription factor that regulates de novo lipogenesis enzymes, was not significantly altered by either genotype or PLX5622 (FIG. 18). Moreover, the expression of the major gluconeogenic enzymes, glucose-6-Docket No. 103362-109W01
[0428] phosphatase (encoded by G6pc) and phosphoenolpyruvate carboxy kinase 1 (encoded by PckP) were downregulated due to loss of Magel2. Interestingly, PLX5622 treatment led to opposing effects on G6pc expression — upregulation in WT mice whereas downregulation in Magel2-null mice (FIG. 18). Protein kinase Ce (PKCe) is thought to play a role in lipid-induced hepatic insulin resistance and the resulting impaired insulin-induced suppression of hepatic gluconeogenesis. Prkce (encoding PKCe) expression displayed a trending interaction (genotype x PLX, P=0.057) with opposing effects of PLX5622 dependent on genotype (FIG.
[0429] 18).
[0430] Western blotting confirmed the reduction in the protein levels of FASN by 35% and PKCe by 44% in Afage / 2-null / PLX (+) mice as compared to ATo c72-null / PLX (-) mice (FIG.
[0431] 19A, 19B). The protein level of SREBP1 was significantly reduced by 24% in Magel2-null / PLX (+) mice (FIG. 19A, 19B). However, liver content of triglyceride was not altered by chronic PLX5622 treatment (FIG. 19C).
[0432] PLX5622 exerts lesser effects in young adult Magel2-null mice
[0433] To determine whether PLX5622’s effects were age-dependent, young female Magel2-null mice and WT mice, 3-5 months of age, were subject to PLX5622 treatment mirroring the middle-aged cohort. Genotype and PLX5622 effects on body weight were significant over the 7-weeks experiment (FIG. 21A, 21B). Weight changes from baseline were not significantly different between the groups (FIG. 21C, 21D). Total weight changes were not affected by either genotype or PLX5622 treatment (FIG. 21E). Interestingly, PLX5622 treatment resulted in significantly decreased food intake regardless of genotypes (FIG. 21F). In contrast to the findings in middle-aged mice, no genotype-effect on food intake was observed in young mice (FIG 2 IF).
[0434] A glucose tolerance test was conducted after 6-weeks PLX5622 treatment. No genotype- or PLX- effect on glucose tolerance was observed (FIG. 22A-22B), differing from findings in middle-aged mice (FIG. 12A-12B). Magel2-mA\ mice showed significantly increased weights of BAT, iWAT, gWAT, and rWAT as compared to WT mice (FIG. 23A-23D). PLX5622 significantly attenuated this genotypic effect in rWAT (FIG. 23D). No genotype- or PLX-effects on liver weight were observed in young mice (FIG. 23E). Of note, the spleen mass was significantly lower in PLX5622 treated mice regardless of genotypes (FIG. 23F). No genotype- or PLX-effects on serum glucose, serum insulin, or HOMA-IR were observed in young mice (FIG. 24A, 24B, 24C). Moreover, genotype-associated hyperleptinemia was notDocket No. 103362-109W01
[0435] affected by PLX5622 treatment (FIG. 24D). Similarly to findings in middle-aged mice, PLX5622 resulted in a robust downregulation of microglia genes in the hypothalamus (FIG.
[0436] 25).
[0437] Discussion
[0438] Standard of care for PWS remains growth hormone therapy and strict supervision of daily food intake. Limitations of growth hormone therapy include requiring patient compliance, lacking efficacy data in older adults, and exclusion of patients with common comorbidities such as severe obesity, uncontrolled diabetes, or active psychosis. Strict supervision of daily food intake and management of emotional reactivity of individuals with PWS results in high levels of caregiver burden, which might exceed that of caregivers for patients with Alzheimer’s and traumatic brain injury. Recent pharmacological developments have been mostly targeting the hypothalamic leptin-POMC pathway through MC4R agonists — Melanotan II (MT-II) and setmelanotide. Additional categories of therapeutics have been tested in animal models and clinical trials at various stages whereas none has been approved by FDA to treat compulsive eating and emotional reactivity, underscoring the urgent need for new therapeutic strategies.
[0439] Previous work has demonstrated that hypothalamic injection of an autoregulatory AAV-BDNF vector efficiently mitigates deficits in the leptin-POMC signaling pathway to alleviate obesity, impaired glucose metabolism, fatty liver, and other metabolic syndrome in genetic, diet-induced, and aging-related models of obesity. The hypothalamic AAV-BDNF gene therapy has shown high level of efficacy and safety in the Magel2-mA\ model of PWS. However, translating hypothalamic BDNF gene therapy to the clinic remains challenging. Thus, alternative approaches to stimulating hypothalamic BDNF were searched for. For example, previous research has demonstrated that environmental enrichment (EE) — a housing condition providing complex physical, social, and cognitive stimulations — exerts a wide range of health benefits across the lifespan of mice. Hypothalamic BDNF has been identified as a key brain mediator coordinating the EE-induced diverse effects on body composition, energy balance, immunity, cancer, behavior, and healthy aging. It was recently reported that EE initiated after the occurrence of metabolic dysfunction could normalize metabolic function in the male Magel2-mA\ mice, mimicking the metabolic effects of hypothalamic AAV-BDNF gene therapy but not the behavioral effects. Unexpectedly, this study suggests hypothalamic BDNF might not be a critical mediator of EE effects in the Magel2-mA\ mice as opposed to wildtype mice.Docket No. 103362-109W01
[0440] These new data suggest biobehavioral interventions could be effective in treating PWS-related metabolic syndromes and thereby warranting further investigation. However, behavioral and lifestyle interventions are difficult to implement in long-term in humans. Hence, small molecules remain the focus of therapeutic development.
[0441] Here, a new category of therapeutics was tested — CSF1R inhibitor in a PWS model, based on clinical and preclinical findings implicating microglia in the pathogenesis of PWS. Chronic CSF1R inhibition by PLX5622 improved metabolic outcomes in middle-aged female Magel2-mA\ mice but not in the young adult mice although depletion of microglia from the hypothalamus did not differ between the two age cohorts. The age-dependent effects of PLX5622 were observed in middle-aged WT mice but not in young mice in a previous study, supporting the hypothesis that aged microglia (manifesting age-related morphological, functional, metabolic, and inflammatory alterations) contribute to age-related metabolic decline. Of note, the current study mirrored the study setting of a previous study in WT mice including strain, sex, age, and PLX5622 regime. Consistent with previous findings, PLX5622 effect on glucose tolerance was unremarkable in middle-aged WT mice. In contrast, PLX5622 treatment ameliorated genotypic increase in food intake and significantly improved glucose tolerance in the Magel2-mA\ mice (FIG. 11F, FIG. 12), indicating therapeutic potential.
[0442] Recent research has demonstrated that PLX5622 does not specifically target microglia but also affects hematopoiesis and macrophages in multiple peripheral tissues (adipose tissue, colon, lung). Robust downregulation of macrophage marker genes and / or genes involved in immune response in the liver was observed, in support of the notion that PLX5622 exerts metabolic effects through peripheral immune modulation. However, the current study was unable to discern the central versus peripheral immune effects of CSF1R inhibition by PLX5622. Amonoclonal CSF1R antibody was found to have no effect on microglia but deplete macrophages across multiple peripheral tissues in mice with an intact blood-brain barrier. Future studies using this anti-CSFIR antibody or clodronate liposomes to deplete peripheral macrophages may help to determine whether PLX5622 modulates metabolic functions in the Magel2-mA\ mice through brain microglia, peripheral macrophages, or both.
[0443] Bosch and colleagues have recently reported that PLX5622 depleted macrophages while increasing eosinophils and group 2 innate lymphoid cells in multiple tissues including adipose tissue, colon, lung, and peritoneum in lean WT mice. CSF1R inhibition by PLX5622 improved hepatic insulin sensitivity but concomitantly impaired insulin secretion through depletion of IL-ip+islet macrophages. Impaired whole-body glucose tolerance was found afterDocket No. 103362-109W01
[0444] 2-months PLX5622 treatment in male WT mice. Studies applied the same PLX5622 regime (1200 ppm in AIN76 diet) but no adverse effect on glucose tolerance was observed in female WT mice regardless of age (FIG. 12, FIG. 22A, 22B). Moreover, PLX5622 resulted in improved glucose tolerance in middle-aged Magel2-mA\ mice. There are differences between Bosch study and the present studies in mouse strain, sex, age when PLX5622 treatment initiated, and glucose tolerance test protocol (time of fast, dose of glucose, etc.), which could explain the inconsistency.
[0445] One new finding of the present study is the liver effects of PLX5622 in the Magel2-mA\ mice. It is reported that PLX5622 treatment led to lesser effects on liver macrophages compared to other tissue resident macrophages in colon, adipose tissue, and lung depending on CSF1R expression levels. PLX5622 did not deplete liver macrophages in male WT mice and reduced liver macrophage frequency in female WT mice after 4-weeks PLX5622 treatment but not at 3-weeks exposure. These data show a PLX5622-induced hepatic gene expression signature characterized as robust downregulation of macrophage markers and inflammatory genes, indicating depletion of liver macrophages in the Magel2-mA\ mice. Immune phenotypes of the Magel2-mA\ mice are largely unknown. Future research should fill in this gap by performing comprehensive immune phenotyping in the Magel2-mA\ mice with and without PLX5622 treatment.
[0446] The hepatic phenotypes mMagel2 deficiency are poorly understood. The present study reveals suppression of genes involved in hepatic glucose production (HGP) and de novo lipogenesis by PLX5622 selectively in Magel2-mA\ mice. It is possible that liver phenotypes of Magel2 deficiency develop at older age and therefore allowing the observation of PLX5622 modulation of liver. HGP plays a crucial role in systemic glucose homeostasis and is regulated through diverse mechanisms. Impaired suppression of HGP is associated with non-alcoholic fatty liver disease. The activation of PKCe is thought to serve as a mechanism linking hepatosteatosis, hepatic insulin resistance, and impaired glycemic control in metabolic disease models. In the middle-aged Magel2-mA\ mice, PLX5622 reduced the protein levels of PKCe concomitant with decreased level of SREBP1, FASN, and G6PC (FIG. 18, FIG. 19). However, liver triglyceride contents were not altered. The functional significance of these molecular changes induced by PLX5622 remains unclear. In addition, PLX5622 treatment improved glucose tolerance in the middle-aged Magel2-mA\ mice but had no effect on HOMA-IR (FIG.
[0447] 12, FIG. 14). Bosch et al. found that glucose uptake to adipose tissue was not altered by PLX5622 in WT mice while glucose uptake to skeletal muscle was trending up associated withDocket No. 103362-109W01
[0448] reduction in systemic triglyceride and alanine aminotransferase and aspartate aminotransferase after 4-5 months of PLX5622 treatment, longer than the 7-weeks duration in the present study. Admittedly, the current study did not examine glucose uptake to metabolic active tissues, or HGP in the Magel2-mA\ mice and therefore unable to identify underlying mechanisms of the improved glucose tolerance in PLX5622 -treated Magel2-mA\ mice.
[0449] One unexpected finding of the current study is that hepatic expression of G6pc and Pckl were significantly lower in the Magel2-mA\ mice as compared to WT mice when increased liver weight occurred (FIG. 18, FIG. 13E). Leptin suppresses HGP and can exert a dual action on nonalcoholic fatty liver disease models — antisteatotic or proinflammatory / profibrogenic, in a context dependent manner. Loss of Magel2 causes leptin resistance in the hypothalamic POMC neurons that results in the metabolic deficits mMagel2-null mice and extreme hyperleptinemia. It remains to be seen whether liver leptin sensitivity is altered and whether leptin plays a role in the liver phenotypes in Magel2-mA\ mice. Further research is required to address these questions. Of note, significant interaction between genotype and PLX5622 treatment was observed in hepatic expression of selective metabolic genes (e.g., Fasn, Scd, G6pc) (FIG. 18), concomitant with significant interaction in glucose tolerance (FIG. 12), worthy of further investigation such as unbiased transcriptomic study.
[0450] It was previously published that Magel2-mA\ mice receiving a control AAV-YFP vector displayed a hypothalamic neuroinfl ammatory gene expression signature compared to WT mice receiving AAV-YFP. AAV-BDNF gene therapy reversed this hypothalamic neuroinflammatory signature in both male and female Magel2-mA\ mice. Here, this genotype-driven neuroinflammatory gene expression signature was not observed in mice that did not receive stereotaxic surgery (FIG. 16, FIG. 25), consistent with the data obtained in the EE study. Together, these findings suggest that stereotaxic injection to the hypothalamus may contribute to the robust stimulation of microglial and proinflammatory markers in the Magel2-mA\ mice receiving the control AAV-YFP, manifestation of increased glial scar in response to surgery as compared to WT mice receiving the same control AAV vector. BDNF overexpression alleviated the genotype-driven heightened gliosis. However, the current study does not rule out the potential role of microglia in PWS pathogenesis due to lack of investigation of microglia morphology and functional state.
[0451] Additional limitations of the current study include investigation in female mice only, small number of mice per group due to the difficulty in accumulating Magel2-mA\ mice, and lack of assessments after cessation of PLX5622. Another limitation lies with the single-gene knockout models of PWS that recapitulate some, but not all, PWS phenotypes. Magel2-mA\Docket No. 103362-109W01
[0452] mice do not mirror the compulsive eating of human PWS when maintained on normal chow diet. It is interesting to see whether PLX5622 exerts more pronounced effects when Magel2-null mice are fed a high fat diet. Testing in other models of PWS such as Snordll6, and Ndn will be needed to assess the therapeutic potential of PLX5622.
[0453] In summary, this study shows that CSF1R inhibition by PLX5622 led to certain metabolic improvement in female Magel2-mA\ mice in an age-dependent manner. PLX5622 treatment resulted in depletion of microglia, downregulation of macrophage markers and genes involved in immune response in the liver, and suppression of genes critical for HGP and lipogenesis in the middle-aged Magel2-mA\ mice. These data provide evidence in support of investigating immune-modulatory therapeutics for the PWS, a genetic disease in urgent need of new therapeutic strategies.
Claims
Docket No. 103362-109W01CLAIMSWhat is claimed is:
1. A method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating Prader-Willi Syndrome (PWS) in a subject in need thereof, comprising administering to the subject an inhibitor of colony stimulating factor 1 receptor (CSF1R).
2. The method of claim 1, wherein the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
3. The method of any of claim 1 or 2, wherein the CSF1R inhibitor is selected from ARRY- 382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
4. The method of any of claims 1-3, wherein the CSF1R inhibitor is PLX5622, or a pharmaceutically acceptable salt thereof.
5. The method of any of claims 1-4, further comprising administering to the subject a growth hormone therapy.
6. The method of any of claims 1-5, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
7. The method of claim 6, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
8. A method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8, wherein PLX5622 is administered orally.
10. The method of claim 8 or 9, wherein PLX5622 is administered at a dose between about 10 mg and about 2500 mg.
11. The method of any one of claims 8-10, wherein PLX5622 is orally administered at a dose selected from about 200 mg, about 400 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1400 mg, or about 1600 mg.Docket No. 103362-109W0112. The method of any of claims 8-11, wherein PLX5622 is administered at least once per day.
13. The method of any of claims 8-12, wherein PLX5622 is administered for at least 14 days.
14. The method of any of claims 8-13, further comprising administering to the subject a growth hormone therapy.
15. The method of any of claims 8-14, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
16. The method of claim 15, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
17. A method for improving glucose tolerance in a subject having PWS, comprising administering to the subject a therapeutically effective amount of a CSF1R inhibitor.
18. The method of claim 17, wherein the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
19. The method of any of claim 17 or 18, wherein the CSF 1R inhibitor is selected from ARRY- 382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
20. The method of any of claims 17-19, wherein the CSF1R inhibitor is PLX5622, or a pharmaceutically acceptable salt thereof.
21. The method of any of claims 17-20, further comprising administering to the subject a growth hormone therapy.
22. The method of any of claims 17-21, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
23. The method of claim 22, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
24. A method for improving glucose tolerance in a subject having PWS, comprising administering to the subject a therapeutically effective amount of PLX5622, or a pharmaceutically acceptable salt thereof.
25. The method of claim 24, wherein PLX5622 is administered orally.Docket No. 103362-109W0126. The method of claim 24 or 25, wherein PLX5622 is administered at a dose between about 10 mg and about 2500 mg.
27. The method of any one of claims 24-26, wherein PLX5622 is orally administered at a dose selected from about 200 mg, about 400 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1400 mg, or about 1600 mg.
28. The method of any of claims 24-27, wherein PLX5622 is administered at least once per day.
29. The method of any of claims 24-28, wherein PLX5622 is administered for at least 14 days.
30. The method of any of claims 24-29, further comprising administering to the subject a growth hormone therapy.
31. The method of any of claims 24-30, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
32. The method of claim 31, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
33. A method for decreasing body weight in a subject having PWS, comprising administering to the subject a therapeutically effective amount of a CSF1R inhibitor.
34. A method for decreasing fat mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
35. A method for increasing lean mass in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
36. A method for decreasing food intake in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
37. A method for decreasing free fatty acid levels in a subject having PWS, comprising administering to the subject a CSF1R inhibitor.
38. A method for preventing, alleviating, relieving, ameliorating, improving, stabilizing, or treating PWS in a subject in need thereof, comprising:(i) obtaining a sample from the subject;(ii) measuring the expression level of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC, or a combination thereof, in the sample compared to a control; and (iii) if the levels of one or more of FASN, Scdl, Scd2, SREBP1, PKCe, or G6PC are elevated compared to control, then administering to the subject a CSF1R inhibitor.Docket No. 103362-109W0139. The method of any of claims 33-38, wherein the CSF1R inhibitor is selected from an antibody or a derivative thereof, an antibody-drug conjugate, a fusion protein, a small molecule, a dsRNA, an siRNA, an anti-sense technology, an aptamer, a gene editing technology, or a combination thereof.
40. The method of any of claims 33-39, wherein the CSF1R inhibitor is selected from ARRY- 382, BLZ945, DCC-3014, GW2850, JNJ-40346527, JTE-952, Ki20227, pexidartinib (PLX3397), PLX5622, PLX7486, or RA03546849 (GENZ-882706 / sCSF-lRinh), or a pharmaceutically acceptable salt thereof.
41. The method of any of claims 33-40, wherein the CSF1R inhibitor is PLX5622.
42. The method of any of claims 33-41, further comprising administering to the subject a growth hormone therapy.
43. The method of any of claims 33-42, further comprising administering to the subject a melanocortin 4 receptor (MC4R) agonist.
44. The method of claim 43, wherein the MC4R agonist is selected from melanotan II (MT-II), setmelanotide, or a combination thereof.
